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 In the United States, there are an estimated 30 million people living with one or 
more rare diseases. Each rare disease impacts fewer than 200,000 people. Small patient 
populations create research and medical challenges. Patients and the healthcare system 
experience high costs. To adequately address patient needs and prepare our healthcare 
system, it is critical that we conduct research that contextualizes the U.S. rare disease 
experience.   
This dissertation includes three related studies that look at the U.S. rare disease 
experience. The first paper investigates the availability and data quality of rare disease 
prevalence estimates and the healthcare infrastructure that could be utilized to establish 
future estimates. The paper found that prevalence estimates rarely follow best practices in 
data quality. U.S. healthcare infrastructure is ill-equipped to track rare diseases and 
produce future prevalence estimates. This could impact our ability to realize and 





 The second paper looked at the caregiver experience navigating health insurance 
using a grounded theory qualitative approach. The paper found that rare disease 
caregivers feel it is imperative to learn how to navigate insurance, especially since health 
setbacks are costly and disruptive. Insurance companies are rarely knowledgeable about 
the disease and interactions are time intensive. Parents are required to meticulously track 
benefits to balance long-term medical needs and financial stability. 
 The third paper investigated orphan drug expenditures in Medicare Part D from 
2013 to 2017. The study found that orphan only drugs represent 8.67% and partial orphan 
drugs represent 6.74% of total aggregate costs. In 2017, the average cost per beneficiary 
for orphan drugs was $92,753 and $3,920 for common drugs. Almost half of orphan drug 
costs are attributed to beneficiaries under age 65.  
 Together, these studies point to the need to invest in our healthcare system and 
explore programs that can address issues of access for patients. Currently, our system is 
not equipped to address patient needs and current funding increases are not sustainable. 
Policy considerations, such as a rare disease national plan, could help ensure rare disease 
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In the United States, there are an estimated 30 million people living with one or 
more rare diseases.1 Rare diseases are defined in the U.S. as a condition impacting fewer 
than 200,000 people.2,3 There are an estimated 6,500-7,000 rare diseases.3 The small 
patient population for each disease creates challenges for research; including for basic 
epidemiological data, natural history studies, and clinical trials for the development of 
treatments.4–9 The lack of research and awareness also means that many medical 
professionals and health insurance companies are unfamiliar with the disease and patients 
may struggle to find basic information about their condition.4,10 This can lead patients and 
their caregivers to feel isolated or unsupported in their attempts to find information or 
resources.6 Additionally, many patients face financial challenges when seeking care.11–15 
“Financial toxicity” is a term identified in the cancer literature to describe the impact of 
economic stress that can impact a patient’s overall well-being, however, this phenomenon 
is not unique to the cancer community.11–14  
An orphan drug is a treatment that has an indication for a disease with an 
estimated population of less than 200,000 people in the U.S. or where it is unlikely the 
manufacturer will be able to recoup the costs of manufacturing the drug.2 Orphan drug 
designation occur as part of the Food and Drug Administration’s (FDA) drug approval 
process.16 Roughly 300 rare diseases (less than 5%) have an FDA approved orphan 
drug.17 The Orphan Drug Act of 1983 established economic incentives to encourage the 
research and development of orphan drugs, including 7-year market exclusivity and fee-




cost was over $46,800 per year and the mean was $87,319.18 The average sales for the 50 
highest cost orphan drugs was $639.5 million in 2017.18 The high cost of orphan drugs in 
the U.S. has resulted in criticisms related to the incentive structures and other 
pharmaceutical company efforts to maximize their profits.19–24  
Challenges faced by rare disease patients are largely universal and are often 
approached as an international public health challenge. Although rare diseases are 
clinically heterogenous, challenges such as diagnosis, finding knowledgeable medical 
providers, and accessing treatments and services are often similar across different disease 
states.4,6 Approaching rare diseases on a global scale allows for international 
collaboration and knowledge sharing that is critical when resources are limited. There 
have been concerted international efforts to bring consistency to the nomenclature of rare 
diseases,25–27 increase the visibility of rare diseases in healthcare infrastructure,28,29 
establish estimated prevalence,30 and establish national priorities for rare diseases.31 
However, there are gaps in the regarding how international efforts are being 
implemented, how patients are being impacted, and what infrastructure exists to support 
these efforts in the United States.  
Although there is a considerable body of research on healthcare access for other 
patient populations, few studies focus on rare disease patients as a group or the U.S. 
capacity to provide access to care. This dissertation research is comprised of three papers 
that look at different topics related to rare diseases and components of the U.S. healthcare 
system. The first paper explores the data quality of available prevalence estimates and the 
infrastructure that exists to establish future prevalence estimates for a sample of rare 




appropriately planning for health expenditures, and educating key stakeholders about the 
disease. The second paper is a qualitative study with caregivers whose children are living 
with metachromatic leukodystrophy (MLD) or spinal muscular atrophy (SMA) that used 
a grounded theory approach to describe caregivers’ perceptions of the health insurance 
experience. The third paper investigates the expenditures of orphan drugs in Medicare 
Part D from 2013 to 2017.  
Together, this research provides an assessment of U.S. specific infrastructure, 
insurance access, and public program spending trends for rare diseases and orphan drugs. 
Individuals living with rare diseases are estimated to represent 10% of the U.S. 
population, but much of our understanding about the rare disease experience comes from 
international studies or studies that focus on an individual rare disease. This research will 
contribute to our knowledge of the patient experience and how policymakers should 
invest in our healthcare system infrastructure to better prepare for current and future 
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RARE DISEASE PREVALENCE QUALITY AND 





In the United States, the Orphan Drug Act (ODA) and the National Institutes of 
Health (NIH) define rare diseases as conditions with less than 200,000 active cases.1,2 In 
the European Union, a disease affecting fewer than 5 in 10,000 people is considered 
rare.3 The Genetic and Rare Diseases Information Center (GARD) at NIH currently lists 
over 6,500 rare diseases.1 Rare diseases impact a variety of body systems and the clinical 
manifestations of rare diseases are heterogenous. Disease onset can occur at any age and 
conditions can be either acute or chronic, but many are debilitating. Although little is 
known about the causes of most rare diseases, an estimated 80% are thought to have a 
genetic component.4 Exposure to environmental toxins, infections, adverse reactions to 
therapies, or immune responses are other known factors of onset, but for some conditions 
the cause is never identified.1,4 Due to the limited research, knowledge, and treatment 
options, many rare conditions are fatal.4,5 It is often difficult for patients to receive an 
accurate diagnosis or to find other individuals with the condition.5–7 Research for rare 
diseases can be difficult based on the small and dispersed patient population.  
Rare cancers share the same definition and many of the same challenges.8 One 
study found that 60 of 71 forms of cancer are considered rare in adults.9 Additionally, in 
another study of cancerous tumors between 22-25% have been estimated to be rare.11 




five-year survival rate of 65% for common cancers.8 Rare cancers are often divided into 
more specific subtypes based on genetic characteristics, meaning that even common 
cancers are becoming increasingly rare.8 Despite limited research overall, rare cancers 
may benefit from efforts to research common cancers.8,10  
Importance of estimating the prevalence of rare diseases  
Estimating the burden of disease is a critical public health function. For most rare 
diseases, basic information such as the natural history of the disease and epidemiological 
data is limited or missing.5,6 Very little is known about the exact prevalence of most rare 
diseases, both in the U.S. and globally.5 A commonly referred to figure estimates 
between 25 to 30 million Americans are living with one or more rare diseases,11 but this 
is a difficult claim to substantiate as the original source and methodology of this 
estimation is difficult to identify.  
Knowing prevalence of a disease provides a baseline to track inequities in the 
impacted population or identify changes in disease burden that may be based on 
environmental exposures, social determinants of health, or structural barriers to care. In 
rare cancers, there is evidence that the distribution, incidence rates, and types can vary by 
region,12 but, without epidemiological data, the cause for these differences cannot be 
explored. Researchers at the World Health Organization also hypothesized that 
epidemiological data contributed to the increased number of treatments and resulting 
health benefits for rare cancers and inborn errors of metabolism.5 Understanding trends in 
morbidities and mortality is necessary to inform a logical approach for disease response 




Healthcare allocation decisions rely on strong epidemiological and actuarial data 
related to the expected healthcare needs and expenditures of the population an entity or 
provider serves. Understanding needs across a population can help identify the specialists 
that will be needed by patients and gaps in services. Estimating the financial impact is 
also important to plan for individual out-of-pocket expenditures and the costs associated 
with disease management. These costs are often high and a source of stress for patients 
and families.13,14 “Financial toxicity” is a growing concept in the research literature that 
describes the personal and treatment related financial burden faced by patients, 
particularly patients with cancer.15,16  
Identifying patients with rare diseases can help inform policies to address the 
financial burden to individuals and the healthcare system. Patient identification is 
important for ensuring a patient base for future clinical trial research.17 It is critical to 
develop evidence-based research on the natural history of a disease and the anticipated 
disease progression. Knowing the number of people impacted by a disease can help 
inform decisions about clinical trial designs and the best way to gather scientific evidence 
for developing treatment protocols. Treatments may only be effective in a portion of 
patients, understanding the total number of people impacted by a condition allows a more 
thoughtful evaluation of clinical effectiveness.  
Prevalence in orphan drug research and development   
The Orphan Drug Act (ODA) incentivizes research and development of rare 
disease products through fee waivers and seven-year marketing exclusivity.2 These 
benefits are based on the estimated prevalence of the targeted disease. Companies 




to establish eligibility for obtaining an orphan designation.18 Drugs are eligible for an 
orphan designation if they are intended to treat a disease that affects fewer than 200,000 
people in the U.S. and there is no expectation of recovering the research, development, 
and marketing costs from U.S. sales of the drug. This process can occur at any point in 
the drug development process, anytime between laboratory drug discovery and clinical 
trials.18 Once the safety and efficacy of the drug has been established through clinical 
trials, the FDA determines the final indications for the drug’s marketing approval.18 
Between January 1983 and August 2018, 503 drugs were approved with an orphan 
indication for drug approval. 
Despite the small market for orphan drugs, the pharmaceutical industry has 
demonstrated the potential for large profits.19,20 Of the estimated 6,500 rare diseases only 
about 300 diseases currently have a FDA approved treatment, leaving many patients 
desperate for successful treatments.21 Some of the criticisms of the ODA include the 
allegation that incentives are exploited to develop drugs that may fall outside of the 
intended scope of the law.19 Of all orphan designation applications received between 
2008 and 2017, 71% were for drugs intended to treat diseases impacting fewer than 
100,000 people18 and the average estimated patient population per orphan therapy was 
5,730.22 Rare cancers have been estimated to represent roughly 30% of orphan drug 
approvals and up to 43% of orphan indications, which is a higher percentage than drugs 
to treat any other category of orphan drug therapeutic use.5,18,22,23 
As part of the orphan drug application process the FDA requires prevalence data 
with references to the estimates’ sources; outdated or international sources need to be 




companies provide these estimates and the FDA validates them. However, in a 2018 
Government Accountability Office (GAO) report, the independent verification of 
population estimates were not conducted for 23 of 148 review templates and for 15 of the 
applications for drugs that were ultimately approved.18 Skipping this verification was 
cited by GAO as one of the concerns related to the review process, but does not 
acknowledge the difficulty in finding and verifying these numbers.  
Measures for establishing disease prevalence 
There are many ways to describe the number of people living with a particular 
disease and different stakeholders have varying priorities that may lead to the use of 
different metrics. Prevalence refers to the number or proportion of people who have a 
particular condition in a population at a particular time.25 This can refer to a point 
prevalence, the number of cases at a specified point in time; or period prevalence, the 
number of cases over a specified period of time.25 These estimates may account for 
changes based on mortality and newly identified cases. Incidence describes the 
proportion of new cases in a time interval.25 Incidence can be expressed as a cumulative 
rate, the total number of new cases, the number of new cases per unit of a population, or 
as a measurement of risk. This paper will refer to prevalence, as this is the measurement 
used for rare diseases in the U.S. and was identified as the preferred epidemiological 
metric in rare disease definitions internationally.26 For some rare diseases the total 
number of identified patients is so small that the estimated disease prevalence is 
described as the number of estimated cases.27    
Many study factors can impact these estimates including the sample population, 




and the methodologies used for data analysis.25 Prevalence data can come from a variety 
of sources including the medical literature, “umbrella” organizations that represent a 
group of related rare diseases, disease specific organizations, government, industry, 
medical records, medical institutions, insurance claims data, and health foundations.28 
When attempting to estimate the number of individuals impacted by a rare 
condition, it is first necessary to determine if a sample would be adequate, or if the 
disease population is so small that a sample is unable to accurately establish population 
level prevalence.29 For example, in one study that reviewed laboratory samples from 
1,825 patients who had two indicator symptoms for lysosomal acid lipase deficiency, 
none of the patients in the study were found to have the disease.30 Rare diseases estimates 
may require infrastructure that has been established to collect prevalence data for the 
disease of interest as other methods may not capture cases of the disease.   
Registries  
A registry is a tool to collect and store data. Commonly identified goals include to 
identify a list of patients, to perform natural history studies, and to support research 
objectives such as for product and treatment evaluation.31–33 Rare disease registries have 
been developed by patient organizations, government entities, and industry. Medical 
centers or designated disease programs within hospitals or treatment centers are also 
natural settings to establish disease registries.34  
Disease registries are well established as a data source for providing population 
estimates for diseases.31,32,35,36 High-quality data relies on well-defined diagnostic 
criteria.29,37 This can be complicated when multiple sites or investigators are involved or 




in. Some diseases may be covered under multiple registries, which increases duplication 
and can divide resources. Privacy laws limit the opportunity to cross-check redundancy 
across different systems.37,38 It is also important to make the distinction between 
duplicate records and individuals who may appear multiple times because they have 
multiple qualifying conditions to be added to the registry.39 
If a registry is not compulsory for all patients, there may be a selection bias in the 
type of patients who decides to participate or who are referred to the registry.29 Patients 
who have more mild forms of a disease or whose care can be managed by their own 
physician are less likely to be referred to specialty centers or seek out additional care. 
Patients may be limited in their ability to travel to specialty medical centers and it is not 
feasible to have multiple geographically diverse centers for diseases with a small 
population.40 Age of diagnosis could also impact where a patient seeks care.41 
Participation may also be influenced by a patient’s perception of his or her benefit, such 
as the availability of therapies or cultural feelings of trust in the medical system.29  
There are a few registries in the U.S. that may provide an opportunity to estimate 
prevalence for the included rare diseases. The Rare Disease Clinical Research Network 
(RDCRN), a network of rare disease centers of excellence within NIH, oversees a 
voluntary patient contact registry.42 The Surveillance, Epidemiology, and End Results 
Program (SEER) at the National Cancer Institute at NIH tracks cancer rates through 
registries in a sample of states which provides coverage for 34.6% of the population.43 
The Centers for Disease Control and Prevention (CDC) funds a program to collect 
information about rare bleeding disorders and patient demographic information through a 




Data within a registry often requires further investigation before prevalence can 
be reported. One study was conducted to assess the quality of data and provide 
prevalence estimates for diseases in RARECARE, a European based rare cancer 
registry.46 The study found differences in the level of uniformity and accuracy of the 
classification across the different types of rare cancers.46 Without clear diagnostic 
criteria, it is often difficult to consistently code and track cases of diseases. Statistical 
analysis to validate estimates often requires comparisons from other data sources, which 
may or may not be available for rare diseases, which makes it challenging to validate 
disease estimates.37,39  
Surveillance and required reporting  
Surveillance is the ongoing collection, analysis, and interpretation of data to help 
prevent disease and injury and to provide scientific evidence for program and policy 
decisions.47,48 This can include passive surveillance of all clinical interactions at certain 
institutions, syndromic surveillance based on clinical features, and sentinel surveillance 
where certain institutions or groups agree to report all cases of a defined condition, often 
these are for disease outbreaks or bioterrorism.47 There are tradeoffs between the 
sensitivity of detecting an event and the simplicity, timeliness, and cost of inclusion.48 
The ability to control or prevent the disease is often seen as the most compelling reason 
to invest in a surveillance system, but other justifications include tracking medical costs 
or mortality rates associated with the condition.47,48 The costs of establishment, 
infrastructure, and maintenance of surveillance systems can be high, but the benefits 




established. Data collected through surveillance are less likely than other methods of 
disease identification to disproportionally include more severe forms of the condition.49 
There are international examples of required rare disease reporting. For example, 
Italy established a country-wide network of accredited centers to serve rare disease 
patients and mandated that new cases be reported to the National Registry of Rare 
Diseases, which now provides country specific incidence measures for rare diseases 
based on population level data.50 Rare diseases are not systematically required to be 
reported in the U.S., but some conditions may be captured in other official public health 
surveillance systems. For example, the National Notifiable Disease Surveillance System 
(NNDSS) at the CDC collects information on a set of infectious diseases across the entire 
U.S.51 Concerns about morbidity and mortality in children, has led to targeted pediatric 
surveillance efforts for some rare diseases.52 Currently, 43 states have birth defects 
tracking programs, 14 of which are funded by the CDC.53 The Recommended Uniform 
Screening Panel is a list of disorders that have been identified by the Secretary of the 
Department of Health and Human Services for inclusion in state newborn screening 
programs.54 However, states decide what is included on newborn screening panels, which 
creates differences across jurisdictions.49 
Disease terminologies and coding systems 
Genetic and rare diseases are generally underrepresented in coding systems.55 
Both registries and surveillance systems are dependent on clear and consistent disease 
identification and coding to maximize the potential for discovery and clinical use.56 
These systems are used by a variety of audiences and were established for different 




efforts to increase rare disease visibility in health information systems and to increase 
interoperability between databases.57–60 Classification systems need to account for 
descriptive and genetic information, especially as new conditions are observed. One of 
the challenges is mapping the terminologies across the existing resources and coding 
platforms that are used to identify and describe rare diseases. A study that looked at 
consistency in coding case reports for a sample of rare diseases found that professional 
coding companies were in agreement on the core concepts 33% of the time.61 
International Classification of Diseases (ICD) codes are used to code diagnoses, 
symptoms, and procedures.62 Globally they are used to track disease statistics and trends. 
In the U.S. they are primarily used for billing purposes. The U.S. first adopted the ICD-9 
codes for use in 1977 and adopted the updated ICD-10 codes on January 1, 1999.63,64 ICD 
codes are used in studies that rely on hospital discharge data, insurance claims, and 
mortality records.65 Most rare diseases are absent from the ICD-10 codes and diseases 
that do exist are often misclassified.66  
One study found that of the 6,519 rare diseases listed by NIH, 11% were broadly 
included in ICD-9 and 21% in ICD-10.57 The study also found that only 25% of the ICD-
10 codes were for only one disease, limiting the level of specificity that can be garnered 
from the data. There are many examples of rare diseases that do not have any ICD code. 
If a disease does not have a specific ICD code, researchers must investigate medical 
records or use proxy indicator variables to create algorithms to identify the disease of 
interest from claims data. This requires dedicated resources to validate information for 




Studies to assess the accuracy of ICD code or administrative data in identifying 
cases of rare diseases have had mixed results.65,67–73 The clarity of the case definition and 
the number of clinical visits by the patient increased the accuracy identifying disease 
cases. Studies that used only ICD codes to assess true cases of rare diseases found 
between 15% and 65% accuracy in identifying cases.65,68,69,74 Differences in the accuracy 
and completeness of capturing cases of a disease between data sets highlights the 
necessity of cross-validating cases. For example, in a validation study to see if muscular 
dystrophy cases were accurately identified in claims and hospital discharge data, 74.02% 
of cases in the claims data were not included in the hospital discharge records.65 
Reference data sets or records to validate cases are not always available for rare diseases.  
The European Commission called for an investment in increasing rare disease 
representation, which will be reflected in the ICD-11 revisions that are being developed 
by the World Health Organization; currently over 5,000 rare diseases are listed in this 
new system.62,66 The roll out and implementation of ICD-11 in the U.S. is unknown. The 
complexities of accurate coding, especially for diseases that clinicians are unfamiliar 
with, will continue to be a barrier for finding and identifying disease cases.   
Challenges in estimations for rare diseases  
Accurate estimates are often impacted by diagnosis related challenges, with many 
rare disease organizations and patients claiming that the actual prevalence is greater than 
the currently identified population.6 The small patient population also makes it more 
difficult to establish tracking systems as the population is likely geographically disbursed 
and difficult to identify. This increases the need for collaboration, but there is evidence 




increased regulatory burden, or unclear benefits.17 Rare diseases are competing for 
limited funding, which can mean an investment in the infrastructure to establish biobanks 
and registries may be hard to justify.12,38  
In Europe there has been an investment in establishing prevalence and 
encouraging country specific rare disease plans.27,75 A preliminary report was released to 
provide initial data on rare disease prevalence for a sample of conditions.76 Some 
therapeutic categories such as pediatric oncology and rare blood disorders are also 
creating frameworks to address healthcare challenges.38,41 In the U.S., leaders at NIH and 
FDA have outlined priorities to address core rare disease challenges faced by patients 
with rare diseases.28 This includes increasing current knowledge of rare diseases, 
additional partnerships with patient organizations, and the need to track genetic 
variability and environmental factors for use in future research.28,77  
Policymakers, patients, medical professionals, researchers, and industry all have 
an interest in understanding the impact of a disease. Understanding prevalence impacts 
healthcare allocation decisions and industry incentives. The GAO has indicated the need 
for increased investment in verification of prevalence data in FDA drug application 
reviews. Researchers rely on epidemiological data to make decisions related to the 
robustness of data for natural history and treatment protocols. Previous rare disease 
prevalence studies have evaluated a single disease78,79 or coding systems62,80 without 
considering other types of infrastructure. It is important to evaluate rare diseases at a 
systems level and determine if disease characteristics impact the availability of 




quantify the scope of our knowledge for U.S. based prevalence estimates or the potential 
to leverage current infrastructure to provide prevalence estimates in the future. 
Methods 
Objectives 
This study seeks to explore two inter-related questions; what is the quality of the 
existing prevalence estimates for a sample of rare diseases in the United States and what 
infrastructure is in place that may be used to ascertain prevalence estimates in the future. 
The research questions for this study are:  
1. What is the availability and data quality for prevalence estimates for a sample of 
rare diseases in the United States?   
2. What infrastructure is available that has the potential to facilitate generating valid 
prevalence estimates for a sample of rare diseases in the United States?   
3. Is there a difference in the availability, information quality, or infrastructure for 
estimates of rare disease prevalence in the United States for diseases that: 
a. have an orphan drug approval compared to those that do not have an 
orphan drug approval? 
b. are rare cancer compared to diseases that are not cancer? 
Conceptual model 
Cleveland’s model of the healthcare environment is the conceptual framework 
utilized for this study.81 (Figure 1) The model underscores the importance of information 
and technology for three key arenas in healthcare; clinical practice, healthcare consumers, 
and research. The model was originally developed to inform the needs of health 




information and technology advancement in the broader healthcare environment. 
Technological advancement and additional healthcare information simultaneously drive 
innovation and must be responsive to healthcare practice and research needs. The model 
is impacted by both internal and external factors including the structure of the healthcare 
system and the values and goals of healthcare delivery.81  
Figure 1: Cleveland's model of the healthcare environment 
 
This study is driven by the informational importance of rare disease prevalence 
data. This information is critical for establishing information about patients (consumers) 
and for creating clinical practice guidelines. Clinical practice is informed by natural 
history of disease progression, which is predicated on understanding the population 
impacted by a disease. Epidemiological, healthcare utilization, and product development 
research all require an understanding of the total population impacted. Technological 
solutions such as registries provide data for determining prevalence. However, the data 
available for prevalence on many health information websites underscore the deficiencies 




Rare disease sample 
To generate a sample of rare diseases, three lists of rare diseases were accessed 
from the GARD website; a list of rare cancers, 82 a list of diseases with FDA orphan 
drugs,83 and the full list of diseases in the GARD database.84 (Figure 2) Data were 
obtained from GARD, the leading U.S.-based government agency for rare disease 
information. The rare cancer and orphan drug lists were combined and redistributed into 
three groups; rare cancers with an orphan drug (group 1), rare cancers without an orphan 
drug (group 2), and non-cancer diseases with an orphan drug (group 3).  Group 4, non-
cancer diseases without an orphan drug, was created by taking the full list and removing 
duplicate conditions from any of the other lists. Microsoft Excel was used to categorize 
each list and obtain a sample of 20 diseases per group for a purposeful stratified sample 
of 80 rare diseases total. (Table 1)  
Figure 2: Flowchart for sample diseases by group 
The full GARD list includes diseases that are not rare, but are included based on patient 
inquiries for information on those conditions. Additionally, disease synonyms are also 
included as separate entries on the list which accounts for the large number of duplicate 





Table 1: Diseases included in the sample 











Group 1 Group 3 
Acral lentiginous melanoma  
Acute lymphoblastic leukemia  
Anaplastic thyroid cancer 
Chronic lymphocytic leukemia  
Clear cell renal cell carcinoma 
Ewing sarcoma  
Familial prostate cancer 
Follicular lymphoma 
Hairy cell leukemia 
Kaposi sarcoma 
Malignant mesothelioma 
Melanoma astrocytoma syndrome  
Neuroblastoma 
Oslam syndrome 
Papillary thyroid carcinoma 
Renal cell carcinoma 4 
Soft tissue sarcoma childhood 
Subependymal giant cell astrocytoma 
Testicular cancer 
Thyroid cancer, follicular 
Acute panmyelosis with myelofibrosis  
Adrenal medulla cancer  
Ameloblastic carcinoma  
Autoimmune lymphoproliferative  
    syndrome  
Basal cell carcinoma, multiple  
Familial pancreatic cancer  
Familial Wilms tumor 2  
Gangliocytoma  
Glassy cell carcinoma of the cervix  
Goblet cell carcinoid  
Infantile myofibromatosis 
Juvenile myelomonocytic leukemia  
Multiple endocrine neoplasia type 2B  
Multiple familial trichoepithelioma  
N syndrome  
Nevoid basal cell carcinoma syndrome  
Nijmegen breakage syndrome  
Oropharyngeal cancer 
Ovarian carcinosarcoma  






Group 2 Group 4 
Cholesteryl ester storage disease 
CINCA 
Cystinosis 
Factor VII deficiency 














Herpes simplex encephalitis 
Hyperkalemic periodic paralysis 
Keratoconus 
Methylmalonic acidemia with  
   homocystinuria 
Homocystinuria type cblD 
Mild phenylketonuria 
Mucopolysaccharidosis type VI 
Myasthenia gravis 
Narcolepsy 
Orotic aciduria type 1 
Prader-Willi syndrome 
Transverse myelitis 
Tuberous sclerosis, type 2 







     syndrome 
Houlston Ironton Temple syndrome 
Hutterite cerebroosteonephrodysplasia  
    syndrome 
Hypomandibular faciocranial dysostosis  
Isochromosome Yp 
Limb body wall complex 
Manitoba oculotrichoanal syndrome 
Mastocytic enterocolitis 
Osteogenesis imperfecta type IV 
Primary pigmented nodular  
    adrenocortical disease 
Seow Najjar syndrome 
Spastic paraplegia 14 
Thickened earlobes with conductive  
    deafness from incus-stapes  
    abnormalities 
Tremor hereditary essential, 2 
 
The FDA orphan drug designations and approvals database was used to collect the 
total number of orphan drug approvals per disease.21 Diseases with an approved orphan 
product are more likely to be the focus of research studies and have a more clearly 
defined patient population due to the clinical trial process. If a disease did not have an 
orphan drug approval, but had an orphan drug designation, that was noted. There is a 




from more accessible treatment centers for both patient information and the collection of 
data. Diseases with orphan drugs and rare cancers have the potential for additional 
information and interest, purposeful sampling was employed to investigate these 
differences.86 The sample size allowed for a feasible investigation into data source quality 
and infrastructure for rare disease prevalence. 
Data sources and searches for evaluating quality of existing prevalence estimates  
The Cleveland model of the healthcare environment81 demonstrates the interplay 
between information and the consumers, clinicians, and researchers who utilize and 
generate the data. The data sources for existing prevalence estimates were evaluated 
based on the standards outlined by Silberg, Lundberg, and Musacchio.87 This framework 
provides principles to evaluate the credibility and usefulness of health data. The four 
areas are authorship, attribution, disclosure, and currency. Authorship refers to disclosing 
the affiliations and credentials of authors and contributors. Attribution is clearly 
displaying references and sources for all content. Disclosure is the ownership of the 
website, including any commercial funding and conflicts of interest. Currency is the date 
that content was posted and updated; for the purpose of this study it will be referred to as 
date. Disclosure was evaluated at the website level and the other areas were assessed at 
the article or webpage level for individual disease listings.  
Eight rare disease, genetic disease, or health information websites were identified 
prior to conducting the study as resources that researchers, patients, or medical 
professionals in the U.S. might access for rare disease information. GARD, Orphanet, 
and NORD are established rare disease specific resources. Genetics Home Reference, 




represent an estimated 80% of rare diseases. Medscape is a popular source for disease 
information and is routinely included as a data source in previous studies that evaluated 
internet based health information.78,88 SEER provides a query function on their website to 
provide cancer statistics based on collected registry information. Descriptions of these 
data sources and the sources’ disclosure information are listed in Table 2.  These sites 
were used to determine if information about the disease was available and if a prevalence 








Table 2: Data sources for prevalence searches for data quality information and infrastructure assessment 
Searches were conducted for two purposes: to evaluate data quality of existing prevalence estimates and to determine the 
infrastructure for future estimates. This chart provides the data source, a short description from the source’s website, the financial 
disclosure for their funding, and if it was used for data quality or infrastructure. 




Genetic and Rare Diseases 
Information Center 
(GARD), National Center 
for Advancing Translational 
Sciences (NCATS) 
Provides the public with access to 
current, reliable, and easy-to-
understand information about rare 
or genetic diseases 
Funded by two parts of the National Institutes 
of Health: NCATS and the National Human 
Genome Research Institute (NHGRI) 
X  
Orphanet Portal for rare diseases that 
includes an encyclopedia of rare 
diseases and associated genes 
Funded by Inserm, the French Directorate 
General for Health, and the European 
Commission through OrphaNetWork, a 
Direct Grant of the 3rd Health Programme of 
the European Union 
X  
Genetics Home Reference, 
U.S. National Library of 
Medicine 
A consumer health website from 
the National Library of Medicine, 
which provides information for the 
general public about the effects of 
genetic variation on human health 
Funded by the U.S. Government X  
GeneReviews, National 
Center for Biotechnology 
Information 
Provides clinically relevant and 
medically actionable information 
for inherited conditions  
Funded by the government through the 
National Institutes of Health and chapters are 









Rare Disease Database, 
National Organization for 
Rare Disorders (NORD) 
Provides brief introductions for 




Primary sources of funding are grants, 
contracts, contributions, and an annual fund-
raising event; enhancements to the Rare 
Disease Database were made possible 
through a grant from the Anthem Foundation 
X  
Online Mendelian 
Inheritance in Man (OMIM) 
Documents genetic defects by 
identified human genes when 
available or genetic phenotypes as 
a proxy 
 
Funded by a grant from the National Human 
Genome Research Institute and individual 
donors; Initial development was supported by 
Johns Hopkins Medicine and a grant from the 
Maryland Department of Health and Mental 
Hygiene 
X  
Medscape Website providing physicians and 
healthcare professionals medical 
news, point-of-care drug and 
disease information, and relevant 
professional education and CME 
Revenue is generated through the sale of 
various types of advertising and sponsorship 
products which include: pharmaceutical, 
biotechnology and medical device 
companies; hospitals and other healthcare 
services companies; health insurance 
providers; companies whose products or 
services relate to health, wellness, diet, 
fitness, lifestyle, safety and illness 
prevention; and various other businesses, 
organizations and governmental entities. 
Advertisements are guided by posted policies.  
X  
Surveillance, Epidemiology, 
and End Results Program 
(SEER), National Cancer 
Institute 
Provides information on cancer 
statistics in an effort to reduce the 
cancer burden among the U.S. 
population. 
Supported by the Surveillance Research 
Program in National Cancer Institute's 







Clinicaltrials.gov ClinicalTrials.gov is a database of 
privately and publicly funded 
clinical studies conducted around 
the world. 
Funded through the Department of Health 
and Human Services 
 X 
ICD-10 and ICD-11 Foundation for the identification 
of health trends and statistics 
globally, and the international 
standard for reporting diseases and 
health conditions. It is the 
diagnostic classification standard 
for all clinical and research 
purposes. ICD defines the universe 
of diseases, disorders, injuries and 
other related health conditions, 
listed in a comprehensive, 
hierarchical fashion 
Developed and distributed by World Health 
Organization (WHO) globally and adapted in 
the United States by the Centers for Medicare 
and Medicaid Services (CMS) and the 
National Center for Health Statistics (NCHS) 
 X 
National Notifiable Disease 
Surveillance System 
(NNDSS) 
Helps public health monitor, 
control, and prevent a sample of 
diseases including infectious 
diseases such as Zika and 
foodborne outbreaks, and 
noninfectious conditions such as 
lead poisoning 
Funded by the U.S. Government  X 
Recommended Uniform 
Screening Panel 
List of disorders that the Secretary 
of the Department of Health and 
Human Services recommends for 
states to screen as part of their 
state universal newborn screening 
programs 










Disease + Organization 
Disease + Registry 
Disease + Medical 
Center 





Disease + [Incidence 
OR Prevalence] 
The National Library of 
Medicine’s full-text repository of 
life sciences journal literature 









Searches were conducted using both the primary disease name and any additional 
synonym names listed in GARD. Google searches were conducted for the disease name 
and the disease name and “organization”, “registry”, or “medical center”. If any of the 
searches resulted in a resource that listed the disease on the website or in the mission 
statement, it was recorded. Some medical centers publish disease encyclopedias from 
third party providers; these sources were not included to limit the over representation of 
available data sources. Organizations, registries, and medical centers were included if 
they were physically located in the U.S. or had a global organizational reach. It was noted 
if the disease was listed under a broader umbrella disease or a more specific sub-type of 
the condition. Two name variables were created; if the disease was listed under a broader 
name on any of the health information websites and if the disease was listed under a more 
specific name on any of the health information websites.  
The data availability variables included if the disease was listed on each of the 
health information website. Prevalence variables included if an estimate was available 
and the quality estimates of authorship, attribution, and date. The total number of 
available prevalence estimates and the total number of available prevalence estimates 
with all three quality factors were also reported. Initial disease searches were conducted 
between June 4 and August 21, 2018. 
Infrastructure for establishing disease prevalence estimates  
Building off Cleveland’s model of the healthcare environment, infrastructure can 
be described as the interplay between information and technology. Prevalence 
information can only be collected or evaluated if technologies and systems are in place. 




paper, prevalence infrastructure refers to the organizations, technology, or data sources 
that provide capacity to provide prevalence estimates. The availability of an ICD code 
was evaluated for the current ICD-1063 system and the working list for ICD-11.89 Disease 
inclusion in the ICD system was coded as not available or a specific disease code exists. 
Two registries were included in the sample the National Notifiable Disease Surveillance 
System (NNDSS) and SEER, a national cancer registry. The Recommended Uniform 
Screening Panel was also reviewed to see if any of the diseases in the sample are 
recommended for newborn screening. 
For searches conducted on Clinicaltrials.gov the total number of search results 
and the number of trials that were considered active were recorded. 90 A trial was 
considered active if it was currently listed as not yet recruiting, recruiting, enrolling by 
invitation, or active not recruiting. Clinical trials indicate the current level of 
governmental and industry investment and interest in a particular disease and the 
opportunity to collect prevalence information.  
A Pubmed search was conducted for each disease using the primary and any 
secondary disease names. An additional search using the disease names and “incidence” 
or “prevalence” was also conducted. The number of results were recorded. The purpose 
of conducting these searches was to see the depth of published knowledge on the disease 
and to provide an indication of the academic and clinical interest in the disease as is 
represented by the research and clinical practice components of the model of the 
healthcare environment. The individual studies were not evaluated as the goal was not to 
determine a specific prevalence for each disease, but to assess what information is 




web sources included in the study routinely synthesize and report the key information 
from academic studies as part of disease listings. Reporting the number of PubMed 
results provides an indication of the any recent findings that may inform reported disease 
estimates in the future. Finally, during the previously described google searches, the total 
number of organizations, disease specific organizations, registries, and medical centers 
were recorded. If a disease had an organization that designated medical centers that was 
also recorded.  
Data analysis  
 Data analysis was conducted in Stata version 13.1. Descriptive statistics were 
calculated and recorded for data quality and infrastructure variables. This included 
frequency counts for categorical data and the mean, standard deviation for continuous 
variables. Means, standard deviation, and p-values were reported. None of the variables 
were found to be normally distributed, so non-parametric statistics were used. Results 
were considered statistically significant at p=.05.  
 Chi-squared tests were conducted to compare the statistical significance of the 
availability of the disease appearing on each health website by group. Simple logistic 
regression was conducted on both name variables; disease listed under a broader name 
and disease listed under a more specific name. Simple logistic regression was also 
conducted for the availability of a prevalence estimate in each health information 
website. (Table 5) The dependent variables were orphan drug, rare cancer, and an 
interaction variable for rare cancer and orphan drugs. Shapiro-Wilk tests were conducted 




additional comparisons by group. The logistic regression results are presented in the 
appendix.  
𝑦 = 𝛽0 + 𝛽1𝑟𝑎𝑟𝑒𝑐𝑎𝑛𝑐𝑒𝑟 + 𝛽2𝑜𝑟𝑝ℎ𝑎𝑛𝑑𝑟𝑢𝑔 + 𝛽3𝑟𝑎𝑟𝑒𝑐𝑎𝑛𝑐𝑒𝑟 ∗ 𝑜𝑟𝑝ℎ𝑎𝑛𝑑𝑟𝑢𝑔 + 𝜀 
 Simple linear regression and follow-up Shapiro-Wilk and F-tests were conducted 
at the disease level for the average number of prevalence estimates available and the 
average number of quality prevalence estimates. Simple linear regression and the follow-
up tests were also conducted to investigate the impact of having an orphan drug and 
being a rare cancer for each of the quality indicators (author, date, and attribution) and for 
having all quality estimates. Means, standard deviation, and p-values were reported. 
(Table 5) 
 Chi-squared analysis was conducted to compare the number of quality estimates 
by group according to the sector of the location for the estimate. The different sectors 
were government funded, industry or private funding, medical center or professional 
society, and organization. (Table 6) 
 Simple logistic regression was conducted for each independent infrastructure 
variable with the dependent variables rare cancer, orphan drug, and the interaction 
variable. These variables included if each disease had an organization, a disease specific 
organization, a registry, a medical center, an organization that designates medical centers, 
an ICD-10 specific code, and an ICD-11 specific code. (Table 7) Follow-up Shapiro-
Wilks and F-tests were conducted and the individual linear regression results are 
presented in the appendix. 
 Simple linear regression for continuous infrastructure variables and follow-up 




number of clinical trials, the number of active clinical trials, the number of PubMed 
disease results, and the number of PubMed incidence or prevalence results.  
Results  
Disease sample characteristics 
Of the 80 sample diseases, 70 included information about therapeutic category in 
GARD. (Table 3) Additional information about disease characteristics were not captured. 
Most diseases (38%) had one therapeutic category listed and 15 diseases (18.8%) had 
two. Ten of the diseases (12.5%) did not have any information listed about their 
therapeutic category. Von Hippel-Lindau disease (group 3) had the most identified with 8 
listed. The therapeutic category with the most disease representation in the sample were 
congenital and genetic diseases (39%), with nervous system (20%), blood diseases 
(13%), and eye diseases (13%).  
Table 3: Therapeutic categories for sample diseases 
Category Total 
Rare Cancer 40 
Congenital and Genetic Diseases 32 
Nervous System Diseases 16 
Blood Diseases 10 
Eye diseases 10 
Not Listed 10 
Metabolic disorders 9 
Skin Diseases 7 
Digestive Diseases 6 
Endocrine Diseases 6 
Immune System Diseases 4 
Kidney and Urinary Diseases 4 
Musculoskeletal Diseases 4 
Newborn screening 4 
Reproductive Diseases 4 
Hereditary Cancer Syndromes 3 
Mouth Diseases 2 




Autoimmune / Autoinflammatory diseases 1 
Ear, Nose, and Throat Diseases 1 
Fungal infections 1 
Parasitic diseases 1 
 
Of the diseases in the sample that had at least one approved orphan drug, 65% had 
more than one drug approval. There was a statistically significant difference (p=.036) in 
the average number of orphan drugs if the disease was a rare cancer (mean=2.9) 
compared to the number of orphan drugs if a disease was not cancer (mean=1.25). Acute 
lymphoblastic leukemia (ALL) (group 1), had the greatest number of orphan drug 
approvals with 13. Four diseases had an orphan drug designation, but the drugs had not 
been approved by the FDA. Of these, 3 were rare cancers. 
Available prevalence estimates and data quality 
Four of the diseases were only identified on the GARD list and could not be 
found in any other data source, these diseases were all in group 4. This difference was 
found to be statistically significant by group (p=.006), orphan drug, and rare cancer status 
(both p=.04). Orphanet included the greatest number of the diseases (78%) followed by 
OMIM (71%), Medscape (53%), NORD (39%), Genetic Home Reference (36%), and 
Gene Reviews (19%).  
Of the diseases included in the sample, 13 (16.25%) were listed under a more 
specific name and 27 (33.8%) were listed under a broader disease name on at least one of 
the health information websites. For example, in GARD the disease chosen for the 
sample was “transverse myelitis”, but in Orphanet a more specific name included two 
additional subtypes and a listing for acute transverse myelitis. Spastic paraplegia 14 was 




group was listed by both a broader and more specific disease name in different sources. 
OMIM had the most diseases (9) listed under a more specific disease name and Medscape 
listed the most diseases under a broader disease name (13). Orphan drug and rare cancer 
were not statistically significant factors for being listed under another name. (Table 4)  
Table 4: Disease name conventions and data websites with prevalence estimates by 
group 
The coefficients, standard error, and statistical significance for individual logistic 





Group 2  
(OD,  
no RC) 
Group 3  
(no OD, 
RC) 






groups that are 
statistically 
significant 
  n=20 n=20 n=20 n=20 n=80   
  n (%) n (%) n (%) n (%) n (%)  
Broader 
name  7 (35) 9 (45) 7 (35) 4 (20) 27 (33.8) None 
More specific 
name 6 (30) 5 (25) 1 (5) 1 (5) 13 (16.3) None 
       
GARD 2 (10) 2 (10) 3(15) 1 (5) 8 (10) None 
NORD 
4 (20) 10 (50) 5 (25) 1 (5) 20 (25) 
Group 3 vs. Group 
4 




2 (10) 10 (50) 5 (25) 2 (10) 19 (23.8) 
Group 3 vs. Group 
4; Group 1 vs. 
Group 2; 
Group 1 vs.  
Group 3 
GeneReviews 0 (0) 4 (20) 4 (20) 1 (5) 9 (11.3) None 
Medscape 
12 (60) 9 (45) 4 (20) 3 (15) 28 (35) 
Group 3 vs. Group 
4;  
Group 1 vs. Group 
2  
OMIM 3(15) 8 (40) 2 (10) 0 (0) 13 (16.3) None 
 
Orphanet included prevalence estimates for the diseases studied more frequently 
than any other source (47.5%) followed by Medscape (35%) and NORD (25%). (Table 4) 




number of prevalence estimates available was statistically significant by orphan drug 
status for NORD, Genetics Home Reference, and Medscape. Rare cancer status was not a 
statistically significant predictor of having a prevalence estimate listed on any of the sites. 
OMIM provided information about known case studies for an additional 24 conditions. 
Of the diseases, 75% had a prevalence estimate listed in at least one of the data sources. 
Of the diseases that had an estimate, 46.78% of the diseases had the same estimate listed 
in multiple places.  
There were a total of 443 prevalence estimates for diseases in the sample, 361 for 
rare cancers and 262 estimates for diseases with an orphan drug. Diseases with an orphan 
drug had an average of 9.03 available prevalence estimates and 2.05 estimates with all 
three quality factors, while diseases without an orphan drug had an average of 2.05 
disease estimates and .575 quality estimates. Rare cancers had an average of 6.55 
prevalence estimates and 1.73 quality estimates, compared to non-cancers which had 4.53 
average estimates and .9 quality estimates. Diseases with an orphan drug that were cancer 
had an average of 9.8 estimates compared to diseases without a drug that were not rare 
cancer that had an average of .8 estimates. (Table 5) Having an orphan drug was a 
statistically significant factor for both having a prevalence estimate and having a quality 
prevalence estimate.  
Of the 443 total prevalence estimates available for any of the sample diseases, 
only 106 (23.93%) had all three quality indicators. (Table 5) Of the estimates, 47.4% had 
attribution, 45.4% had date, and 32.7% listed authorship. Of the estimates that had 
attribution, 30.5% of them only included the name of the original source for the content 




9.7% of estimates provided an organizational editorial board for the author, but did not 
identify a specific person who was responsible for the content. Including a date was 
statistically significant by rare cancer status. Within the estimates, there was no 
statistically significant difference in having all three quality factors by orphan drug or 
rare cancer status. 
Table 5: Prevalence estimates with data quality factors 
The coefficients, standard error, and statistical significance for individual logistic or 
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Attribution 99 (50.51) 67 (40.61) 
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Of the estimates, 39.3% were listed on a medical center’s website and 31.4% were 
listed on government funded sites or data sources (including Orphanet). (Table 6) 
Orphanet was the source with the single highest number of estimates, 38. Estimates 
posted on industry or privately funded sites had the highest percentage of including all 
three quality factors (64.3%). Government funded websites had the highest number of 
quality estimates, but this represented only 38.9% of the estimates available on these 
sites. Only one estimate (.57%) listed on a medical center website included all three 
quality factors. 
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Infrastructure for prevalence estimates 
Having an orphan drug was a statistically significant predictor of having an 
organization, medical center, registry, ICD-10, and ICD-11 specific code. (Table 6) A 
total of 50 (62.5%) diseases had at least one patient organization. On average there were 
3.1 organizations per disease. (Table 7) Neuroblastoma (group 1, cancer and has an 
orphan drug) had the most organizational representation with 19 organizations. Being a 




organization. Only four the diseases in group 4, not cancer and no orphan drug, had 
organizational representation. Disease specific registries were available for 19 diseases. 
Medical centers were identified for 56 (70%) of the diseases. Testicular cancer (group 1) 
had the most identified medical centers with 96. Seven of the diseases had an 
organization that designates medical centers of excellence for the disease of interest. 
Only 19 diseases (23.75%) had an ICD-10 specific code and 43 diseases had an ICD-11 
specific code (54%). 
The total number of diseases listed in the SEER Coding and Staging Manual was 
not statistically significant by orphan drug status (p=.677). None of the diseases in the 
sample were included in the NNDSS system. One disease, methylmalonic acidemia with 
homocystinuria (group 2), was listed as a secondary condition in the Recommended 
Uniform Screening Panel (RUSP) for newborn screening.  
Table 7: Prevalence infrastructure by group 
The coefficients, standard error, and statistical significance for individual logistic 
regression results can be found in Appendix E.  




















significant   n=20 n=20 n=20 n=20 n=80  
  n (%) n (%) n (%) n (%) n (%)  
Organization 
exists for disease 17 (85) 17 (85) 12 (60) 4 (20) 50 (63) 
 
Group 2 vs. 
Group 4; Group 
3 vs. Group 4 
A disease specific 
organization exists 6 (30) 10 (50) 5 (25) 2 (10) 23 (29) 
 
Group 3 vs. 
Group 4 
A registry exists 4 (20) 11 (55) 3 (15) 1 (5) 19 (24) 
Group 3 vs. 
Group 4; Group 




A medical center 
exists 17 (85) 17 (85) 14 (70) 8 (40) 56 (70) 
Group 3 vs. 
Group 4 
ICD-10 Specific 7 (35) 8 (40) 3 (15) 1 (5) 
19 
(23.75) 
Group 3 vs. 
Group 4 
ICD-11 Specific 14 (70) 14 (70) 5 (25) 3 (15) 36 (45) 
Group 3 vs. 
Group 4; Group 
1 vs. Group 2 
 
Table 8: Continuous prevalence infrastructure components by group 
The coefficients, standard error, and statistical significance for individual linear 
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The average number of PubMed search results per disease were 7,834 for Group 1 




PubMed results with 38,880 and Acute lymphoblastic leukemia (ALL) (group 1) had the 
highest number of search results for incidence or prevalence data in PubMed (2,510). 
There was a statistically significant difference in the number of PubMed results when 
comparing Group 1 with either Group 3 or Group 2. One disease, Hutterite 
cerebroosteonephrodysplasia syndrome (group 4), had no results and 7 diseases did not 
have any search results for incidence or prevalence data in PubMed. 
There were clinical trials registered for 71.25% of the diseases and active clinical 
trials for 60% of the diseases. (Table 7) The average number of active clinical trials for 
diseases with an orphan drug were 55.65 compared to 5.83 for diseases without an orphan 
drug, there were statistically significant differences between diseases in Group 1 and 
those in Group 3 or Group 2. (Table 8) Only 4 diseases in Group 4 had active clinical 
trials, while there were 19 (95%) in Group 1.  
Discussion 
The Cleveland model of the healthcare environment details the relationship 
between patients, clinical practice, and research to both inform and utilize information 
and technology.81 For rare diseases this interplay provides context for the availability of 
prevalence information and the related challenges of rare disease knowledge and data 
quality. However, the data quality of that information is not meeting core standards of 
data information.87 Overall, few rare diseases report the data sources used to establish 
prevalence. Diseases that have an orphan drug are statistically more likely to have 
infrastructure in the form of organizations, identified medical centers, registries, or ICD-
11 specific codes to establish prevalence estimates in the future. An orphan drug approval 




Rare cancer was not seen to be a statistically significant factor in information availability, 
quality, or infrastructure. Our methods to establish prevalence through registries, claims 
data, or other methods require a substantial investment of resources and are not always 
reliable without a substantial sample size, a clear disease definition, and a significant 
investment of resources,33,35,70–73,91 qualities many rare diseases do not exhibit.  
Limitations 
It is possible that the total prevalence of a disease is a confounding factor for the 
availability of information. For example, the identification of 500 cases of an emerging 
disease might result in more attention and opportunities for further investigation 
compared to a disease with only 50 identified cases. This study was meant to assess what 
we know about the prevalence of rare diseases or how we can ascertain this information, 
but the number of people impacted is likely a contributing factor to what is known. It 
would have been difficult to control for prevalence, based on the limited available 
information. This both contributes to the problem and highlights the need for the study.  
It was not possible to complete searches for all 6,500 rare diseases; a sample of 80 
rare diseases was chosen to allow for representation and analysis that would allow for 
informed comparisons by group, rare cancer, and orphan drug status. The sample did not 
control for disease diversity beyond the status of having an orphan drug or being a rare 
cancer. The overall heterogeneity of rare diseases made it difficult to account for the 
many potential factors that could be relevant in available prevalence information.  
Age of onset and therapeutic category are two areas that could be confounding 
factors within the results. If some therapeutic categories have more rare diseases, the 




diagnosis, tracking, and patient support. Age of onset could impact prevalence estimates 
or infrastructure due to an increased concern about pediatric conditions and the loss of 
life due to early mortality. Therefore, diseases with pediatric onset may have a 
disproportionate level of infrastructure compared to later onset diseases. Ethical 
considerations for testing therapies for childhood diseases may mean that there are fewer 
orphan drugs for childhood diseases. Information about the breakdown of therapeutic 
categories for all rare diseases or differences based on age of onset are not available and 
could not be controlled for the purpose of this study.  
The disease sample disproportionately included melanomas; 3% of rare cancers 
on the GARD list and 12% of cancers with an orphan drug are melanomas. In this study, 
25% of rare cancers with an orphan drug are melanomas. Despite these sample 
limitations, the sample size is believed to be adequate to assess the current state of 
available infrastructure and to guide for future investigations or policy considerations.  
The identification of the GARD list of rare diseases to generate the sample was 
based on GARD’s status as one of the authoritative resources and leaders for rare disease 
information in the U.S. The list included diseases that were difficult to identify in other 
sources as the listing sometimes only included the name without a disease description. 
For example, one of the sample diseases was Renal cell carcinoma 4. There was no 
description of the disease listed in the GARD database, therefore it was difficult to 
determine if this was Stage 4 or Type 4. The GARD list also may have had duplication 
beyond what was indicated. In a few cases, other data sources indicated that a disease 
synonym existed, but in GARD that term had its own listing, indicating a unique 




the same condition or that there is not scientific consensus on the disease definition. This 
could result in misclassification of the overall availability of information for the disease. 
This inconsistency is a valuable finding in understanding how we should approach the 
dissemination of rare disease information in the future and the challenges individuals face 
when searching for high-quality information.   
There is also the potential of disease misclassification into the wrong group. For 
example, on the GARD website, “melanoma astrocytoma syndrome” is listed as having 
an approved drug, Aldesleukin92. However, the website for this condition states that it is 
“indicated for the treatment of adults with metastatic renal cell carcinoma (mRCC) or 
metastatic melanoma (mM)” and neither the prescribing information nor the drug website 
specifically mention “melanoma astrocytoma syndrome”. It is possible that the drug 
treats all forms of melanoma, that it is used off-label, or that this syndrome is not well 
defined. Either way, the current information brings up questions related to how we name, 
classify, and describe diseases.  
Some of the diseases included on the list were “familial” versions of other 
conditions, such as “familial pancreatic cancer”. The distinction of a familial form of the 
condition has clinical importance for the risk of inheritance of the disease, but is difficult 
to differentiate in most data sources and requires family history in addition to an 
individual’s medical records.93,94 Familial diseases were considered distinct forms of the 
disease for the purpose of this study, but there are inconsistencies related to the 
importance of that distinction across data sources and in practice.  
Systematized Nomenclature of Medicine- Clinical Terminology (SNOMED) is 




SNOMED can capture clinical observations and was established to integrate with ICD-10 
codes as part of the electronic health record systems.95 SNOMED nomenclature and use 
happens largely behind the scenes in most electronic health records systems. Despite 
SNOMED being included in other studies to evaluate coding language for rare diseases, it 
was not included in this study as it is not extensively used for research purposes in the 
U.S. as most methodologies rely on ICD codes.80 
The number of PubMed search results could be skewed by additional factors such 
as diseases that had an animal form. It is also possible that a study had the primary goal 
of estimating the total number of people impacted by the disease, but it did not appear in 
the “incidence or prevalence” search. PubMed searches were meant to serve as indicator 
variables for the extent of scientific interest and current investment in the disease and the 
impact is likely minimal. 
U.S. based clinical trials are required to be submitted and listed on 
ClinicialTrials.gov if the study purpose is to evaluate a drug, biologic or device.96 
Researchers can voluntarily submit their study if they are investigating other methods, 
but investigators conducting observational studies are not required to do so. Therefore, it 
is likely that diseases that have an orphan product approval in the U.S. would have had a 
study that was required to be posted on the site. The use of actively recruiting or on-going 
studies is a more accurate indicator of current or future research investment.  
Data quality was assessed using a widely cited set of principles.87 Some of the 
disease estimates were identified as having attribution, but the listed information only 
provided an organization source, such as the American Cancer Society or Orphanet. The 




listed author was only at the organizational level, such as a medical advisory board for 
the organization. This would make it difficult to trace the data estimate to the original 
source. The author or attributed sources were often trusted organizations who would have 
access to expert reviewers, but it may misrepresent the reader’s ability to accurately 
identify how estimates were determined. Authors were listed at an organizational level 
for 9% of the estimates and 30% for the attribution of estimates. The majority of these 
estimates were missing one of the other two data quality measures, limiting the overall 
impact of misclassification of the estimate as high-quality data.   
Identifying specific rare diseases in data sources  
Identifying a disease across case studies and in medical terminologies is critical to 
advancing research. The importance of consistent identification and naming conventions 
for rare diseases has led to the establishment of collaborations such as the Monarch 
Initiative and IRDiRC to map terminologies across resource sites and to accelerate 
translational research.60,97,98 Some data sources, such as Orphanet, provide the known 
linked identifiers from a variety of places, including OMIM, ICD-10, and GARD. 
However, other resources are more isolated in the information that they provide, which 
makes it more difficult to track diseases with less information across data sources. 
Although NIH collaborates on many of the international initiatives, the data resource list 
does not currently reflect some of the on-going international efforts to improve naming 
conventions, such as providing the identifier for other sources.  
Personalized medicine and a trend towards common diseases being 
subcategorized into distinct disorders are also impacting the healthcare landscape.17,28,38 




and the types of treatments that are in development.17 In 2010, an estimated 10% of FDA 
approved drugs contained pharmacogenomic information.77 Targeted drugs have the 
potential to result in fewer adverse events and decrease healthcare costs.100–102 This 
approach requires clinically validated biomarkers and evidence that the resulting 
treatment is effective, safe, and more cost-effective than drugs already on the market. 
Understanding the relationship between prevalence, personalized medicine, and drug 
incentives will be necessary to prepare for costs and potential inequities in our healthcare 
system. As our ability to pinpoint genetic variations of diseases increases, we will need to 
find ways to provide information on these differences to clinicians and patients. Our 
infrastructure to identify and treat these patients may not be ready for these types of 
advances. This may to lead to increased inequities based on patient characteristics and the 
ability to access to elite providers.   
Beyond genetic variation, multiple diseases in the sample were listed under a 
broader umbrella term in both NORD (6.25%) and Medscape (23.75%). Grouping 
diseases under umbrella terms is useful for pooling resources and sharing medical 
advances; rare diseases have even been credited with providing medical insights for 
related common conditions.91,103 However, evidence indicates that small differences in 
cancer type and location can impact prognosis17 and the increasing use of genetic data for 
biologics101 necessitates specificity. Understanding the differences between diseases 
within an umbrella grouping can impact treatment effectiveness and health outcomes. 
There is also a statistically significant difference in the likelihood of being listed under a 
more specific name according to the presence of an orphan drug, which may indicate 




The importance of this consistency and ability to follow the depth of current 
medical knowledge may not be necessary to the average medical consumer. However, 
many rare disease patients and caregivers express the need to become experts in their 
disease due to the limited information and knowledge among many health experts.7,104,105 
Many rare disease patient organizations, which are often founded by caregivers, become 
the driving force behind research and product innovation.106–110 Finding ways to link data 
across information sources becomes necessary to ensure that clinicians writing case 
studies, researchers conducting studies, and patients establishing organizations can work 
together to identify advances.    
Prevalence data quality 
Statistical analysis for prevalence requires knowledge about the anticipated size of 
the population, for small populations these variations can impact the accuracy of 
prevalence calculations.25,37 The need for baseline information and an ability to identify 
the source of these estimates is a necessity for data integrity. Data sources, even trusted 
sources such as medical centers and government websites do not always provide the 
information needed for individuals to assess the quality or relevance of the data. In the 
Google searches for centers and organizations estimates for diseases were often posted 
without any reference to the data source for the estimate. Often, these estimates were 
consistent across multiple sites, without attribution. 
Industry had the most complete data quality information (64% of estimates) 
compared to any other source. This may be attributed to the fact that they are less likely 
to have implicit trust from consumers. It should be concerning that only 1 estimate 




should provide the information necessary for individuals to find the original source of the 
information to allow them to critically assess the information and current scientific 
knowledge. 
The primary audience of interest for health websites informs the content and 
depth of technical language. The funding source may also impact the type of content 
displayed and the date of updates. NORD, Genetic Home Reference, and Medscape were 
the sites with a statistically significant difference in posted information by orphan drug 
status. OMIM only had two prevalence estimates for diseases without an orphan drug. 
The listings in OMIM are often the synthesis of other published studies to identify and 
link information about genes and disease phenotypes, which could explain why diseases 
with less published data from other sources are unlikely to appear in this data source. 
Some of the entries in NORD’s Rare Disease Database are provided through educational 
grants from pharmaceutical companies or disease specific organizations.11 Similarly, 
Medscape receives grants and advertising revenue.111 Both organizations have editorial 
and conflict of interest policies on the content of articles, but the decision related to 
which content is produced, is likely impacted by the availability of resources and easily 
identifiable disease experts.  
Keratoconus (Group 2) had the highest number of consistent estimates (19). Of 
these, only 1 referenced the source of these estimates, a study published in 1986 that 
found a total of 64 residents of Olmsted County, Minnesota were diagnosed between 
1935 and 1982.112 Would we still consider these results generalizable to a modern US 
population? More recent studies have been conducted internationally and indicated that 




additional prevalence studies have been conducted. The most recent orphan drug 
designation was filed in 2017, indicating that pharmaceutical companies may still be able 
to benefit from current prevalence estimates. However, by not investing in new estimates 
we might be missing other key data trends such as disparities in who is impacted by the 
condition or inequities in who is being diagnosed or treated. This condition has an 
effective treatment, but for other conditions outdated statistics may represent missed 
opportunities.  
Infrastructure for prevalence estimates 
The findings related to ICD-10 codes are consistent with similar investigations in 
the literature.62,66 It is well documented that ICD-10 codes do not accurately capture rare 
diseases. A disease with an approved orphan drug would necessitate a billing code for 
submitting claims to the insurance company, therefore, it is not surprising that there was a 
statistically significant difference based on orphan drug status for ICD-10 and ICD-11. 
Rare disease patient organizations have a well-documented history of driving 
change in the rare disease space and collaborating with the other stakeholders. However, 
if a disease does not generate interest or support from beyond the identified population, 
the organization may not be financially sustainable. Which may indicate why the 
presence of an orphan drug impacts the likelihood that an organization for the disease 
exists. Rare cancer status was a statistically significant indicator of having an available 
patient organization, but not for the number of organizations. Many of the cancers 
included in the study were found to be naturally grouped with other diseases or listed 
under broader disease groupings. It is possible that rare cancers, despite being classified 




supports them. There may be a closer alignment to cancer, rare or common, then to rare 
diseases. Many top selling orphan drugs are oncology drugs,19 and this study found a 
relationship between rare cancer and a higher number of available orphan drugs. 
Decisions to reinforce infrastructure and stimulate the investment in rare diseases, should 
consider the goals and recognize the disparities in what is available based on disease and 
therapeutic category.   
Registries, organizations, and medical centers for rare cancers often did not 
include the specific subtypes of the cancer included in the study. Oncologists may be 
capturing this information, but it is not being reported in scientific and patient resources. 
It is also possible that the federal investment in cancer infrastructure through SEER 
changes the need for smaller registries to be established and maintained for individual 
cancers. Registry data does not always include the detailed site and histology information 
for rare cancers.46 Indicating a need for a better way to capture this information in the 
future.   
Having an orphan drug is a statistically significant factor for more infrastructure. 
However, it is difficult to determine the direction of the relationship between 
pharmaceutical interest and infrastructure. Four diseases had an orphan designation 
without an FDA approval for any orphan drug. There was a statistically significant 
difference (p=.0002) between the average number of prevalence estimates available for 
diseases with an orphan designation (7.5) compared to diseases that did not have an 
orphan drug designation (1.44). These diseases were not statistically more likely to have 
an organization and only one of the four had an ICD-10 code. This could support a theory 




investment and the additional infrastructure follows, potentially with pharmaceutical 
support.  
Policy implications  
Rare disease patient organizations are an increasingly integral force in driving 
research.35,106,108,109 Establishing systems that can provide higher quality raw data could 
help drive other research goals; establishing natural history progression, investigating 
disease risk, identifying treatment protocols, and developing treatments. The pace of 
scientific advancement, especially in genetics, provides hope to many patients.56,102,114 
There are international efforts underway to leverage these technologies by mapping 
disease terminologies across data sources97,98 and establishing prevalence estimates.76  To 
realize these benefits in the U.S., especially with the geographic diversity and inequitable 
access to high quality healthcare, supportive infrastructure must be established to support 
these efforts in a systematic way instead of a disease-by-disease approach.   
When discussing the U.S. definition for rare diseases, it is important to 
acknowledge that the current definition is a static prevalence. As the U.S. population 
grows, the threshold for attaining rarity will become less inclusive over time, rather than 
staying proportional to the population. In 1983, the year the Orphan Drug Act was 
passed, the population of the U.S. was 233.8 million115, in 2019 the estimated population 
was roughly 328.6 million116. In 1983, to be considered a rare disease it needed to impact 
.086% of the population, whereas in 2018 a disease would need to impact .061% of the 
population. Although this difference is currently minimal, over time, we must decide if 
this metric needs to be reconsidered and if the definition itself can help us meet policy 




As is outlined in the healthcare infrastructure model, the technological needs and 
information are both being generated and demanded by consumers, researchers, and 
clinicians simultaneously. This can occur as new conditions are being identified and 
information is being collected across platforms. Disease experts and clinicians, guided by 
patients, should drive infrastructure needs, instead of pharmaceutical companies. It is not 
possible to ascertain the direction of the relationship between a disease having an orphan 
drug and additional infrastructure. It is difficult to determine if a disease requires 
infrastructure prior to attracting pharmaceutical interest or if a disease gains infrastructure 
support based on pharmaceutical investment.  
The heterogeneity of rare diseases and the size of the U.S. makes it unlikely that a 
one-size fits all approach would adequately account for the diverse needs associated with 
capturing, tracking, and estimating prevalence. Most rare diseases are unlikely to meet 
the criteria needed to justify establishing a surveillance system.47 Under our current 
system, organizations or medical centers are the most likely champions to represent a rare 
disease and invest in registries or other disease specific structures. Ultimately, 
pharmaceutical companies have an interest in prevalence, but not until they have a 
product in development. Leveraging long-term pharmaceutical interest in prevalence 
estimates may provide an opportunity to utilize some of the application fees for the FDA 
approval process to establish a fund to conduct and validate rare disease prevalence 
studies. 
Entities that maintain their own tracking infrastructure such as registries should 
investigate data sharing agreements with entities tracking the same diseases.39,58 Of 




This represents a splintering of resources and knowledge that could complicate the ability 
to validate estimates. Medical centers may be able to attract patients if they establish 
disease centers of excellence within their facility. Patient organizations have begun to 
identify and designate these entities to provide patients with recommendations for where 
to find disease experts. Patients who are not satisfied with care at their local medical 
facilities may seek a specialized medical center. These centers will not be able to develop 
in all geographic regions. 
Clinicians are on the front line of disease tracking. Even if a patient seeks out a 
patient organization and decides to independently join a registry, that would be based on 
a diagnosis they received from a physician. Physicians are trained to look for the most 
likely solution to a problem, “when you hear hoofbeats, think of horses not zebras”. If a 
condition is only documented as impacting a handful of patients, it may be more difficult 
for a medical professional to consider the possibility of the rare “zebra”, leaving patients 
without a diagnosis or appropriate care. Diagnosis is a well-documented challenge for 
rare disease patients, which may result in multiple interactions with the healthcare system 
in multiple locations before an accurate diagnosis is achieved.28 Disease experts may be 
outside of an individual’s geographic region65 and understanding care patterns is crucial 
when assessing the limitations of using clinical data, especially if it is limited to one site 
or database.73 Research is also reliant on collecting substantial evidence prior to 
developing treatment guidelines, but understanding what is substantial must be based on 
the estimated population. Payers may be reluctant to authorize experimental procedures 
without clear medical guidelines, especially if the evidence is less robust then for a 




Researchers who investigate estimates are reliant on ICD codes to indicate a 
specific condition or to sort through case notes and indicator codes to validate the 
diagnosis. Studies have found that different individuals code and interpret medical 
conditions differently.61 It is important to work with clinicians to understand how we can 
better interpret clinical notes to further validate diseases, especially ones that do not have 
a specific ICD code. This will become more critical as genetic data becomes more 
prominent in medical practice, a shift that many physicians feel ill-equipped to handle.117 
Rare diseases do not provide a compelling case of the ability of our current infrastructure 
to track and disseminate this information to a broad clinical base.  
Data quality will increase if there is greater collaboration between clinicians and 
those working to provide these estimates; researchers, registries, and organizations.46 
Maintaining high-quality biologic samples and biobanks with appropriate informed 
consent from patients can provide a base of samples for future investment and validation. 
Centralized infrastructure for labs could provide greater consistency with the 
identification and diagnosis of rare conditions.46 Establishing rare disease centers of 
excellence, such as through expanding the Rare Disease Clinical Research Network42 
would provide more opportunities to collect prevalence data and increase our ability to 
track natural history data.   
The U.S. should continue to collaborate with international efforts to address rare 
diseases as a global public health challenge. The importance of including the patient 
voice in drug development and state-based coalitions is well established.106 To identify 
the appropriate next steps and ensure that rare diseases are being addressed holistically 




been successful patient advocacy representation in the efforts to advance the science 
behind rare diseases, but national plans can address aspects of care including 
coordination of care, patient engagement, and early access drug programs.75 A national 
plan would help identify and create a roadmap to prioritize investments that would 
benefit the rare disease community, such as adopting the finalized ICD-11 codes. 
Despite a number of systems to identify high-quality medical or health 
information,118 many sites do not follow core standards for high-quality health 
information. Even trusted sources such as government websites should commit to data 
quality standards to ensure consumers can identify the source of information. Rare 
disease studies may be limited in scope and it is important for individuals to evaluate the 
quality of the information source. Identifying the source of previous estimates may help 
establish new networks for collaboration. Patient advocates or emerging researchers may 
want to contact the authors of previous studies to establish partnerships at clinical sites or 
to establish data sharing agreements with registries.  
Any new policies around infrastructure and tracking must also consider the ethical 
components of patient identification.  HIPPA protections limit the ability to share data 
across platforms or with unauthorized entities. Although it is critical to avoid duplication 
of data for diseases that may have multiple registries, these needs must still protect 
patients and gather consent. Despite current protections for individuals with preexisting 
conditions under the Patient Protection and Affordable Care Act’s (ACA),119 there is 
political pressure to dismantle this law. It would be naïve to ignore these concerns 
without ensuring the societal interest in patient identification is not at the expense of 





Current infrastructure to provide prevalence estimates would require collaboration 
with medical centers, organizations, registries, and researchers conducting insurance 
claims studies using ICD-10 codes. For the majority of rare diseases, this would require 
establishing a clearer disease definition and validating the name of the disease across data 
sites. Data quality for existing rare diseases is often inadequate according to key data 
quality metrics. Rare cancers are not more likely to have better quality data or 
infrastructure compared to other rare diseases. Diseases with an orphan drug have more 
sources of disease information, but this may not result in higher quality prevalence 
estimates overall. Diseases with an orphan drug do have more available infrastructure, 
but the direction of this relationship between information and pharmaceutical investment 
cannot be determined. Establishing data infrastructure and investing in the verification of 
prevalence data is important for clinicians, patients, and researchers. The U.S. should 
continue to collaborate internationally on initiatives to support rare disease research and 
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THE HEALTH INSURANCE EXPERIENCE AS DESCRIBED 
BY RARE DISEASE CAREGIVERS 
 
Background 
Rare diseases are defined in the United States as conditions with less than 200,000 
cases.1,2 The National Institutes of Health currently lists over 6,500 identified rare 
diseases. A commonly cited estimate indicates between 25 to 30 million Americans are 
living with a rare disease.3 Rare disease patients experience barriers to optimal health 
outcomes due to an inability to receive a timely diagnosis, insufficient treatments, lack of 
knowledge among some healthcare providers, and limited knowledge or research about 
the condition.4–10 Patients and their caregivers often feel isolated and helpless.8,11 In one 
study, parents expressed concerns about the ability to access needed genetic 
information,12 which is often key for a diagnosis. 
Although not all rare diseases are chronic, the literature around the chronic 
disease community can provide insight for the rare disease experience, which is often 
similar. Care coordination is critical for individuals with chronic care needs and parents 
often must take responsibility for coordinating the care team and being the expert in their 
child’s care.6,7,13 Care access points for medical equipment and therapy are often unclear, 
especially when services are provided at a community level.14 A tool was created as the 
result of a qualitative study6 and online survey7 to measure the supportive care needs of 
rare disease caregivers. The tool was developed to be used in both a clinical setting and in 




necessary support included understanding the disease, working with health professionals, 
emotional issues, and financial needs.15 In the development of this tool and in other 
broader studies on rare disease experiences, caregivers expressed fear around the 
uncertainty of the health of their family member, their financial ability to respond to 
health needs, and future life decisions.6–8  
Achieving positive health outcomes is dependent on healthcare access.16,17 Access 
depends on a variety of well-established factors including geographic, demographic, 
structural, and financial.17,18 Health insurance is a critical factor for needed healthcare 
utilization, but in the U.S. insurance access and quality are highly variable.19,20 In 2016, 
49% of the U.S. population received coverage through employer sponsored insurance, 
35% were on public insurance, 7% through non-group insurance, and 9% were 
uninsured.21 According to the National Health Interview Survey working-age individuals 
with disabilities are more likely have coverage through Medicaid, Medicare, or military 
benefits and less likely to be uninsured than nondisabled individuals.22 Supplemental 
programs such as early intervention (EI), which provides services for children at risk for 
development delays are often critical for accessing needed services, such as therapy.23 
However, changes in eligibility status for Medicaid and EI have resulted in geographic 
variations of care and quality outcomes.20 Individuals residing in Medicaid expansion 
states were more likely to have coverage.24  
Respondents to the Health Reform Monitoring Survey, a nationally representative 
sample of U.S. adults, found that even with health insurance, 17.9% of families and 
23.3% of individuals reported having problems paying for medical bills in 2016.25 In a 




concerned about healthcare costs and an estimated 15 million individuals deferred or 
skipped recommended medicines due to costs.26  
Maintaining consistent health insurance coverage is a high priority for individuals 
with high healthcare costs. One study of the commercial health insurance marketplace 
found that families that include an individual living with a rare disease have longer 
retention with their health insurance plan (p<.0001) than families without at least one rare 
disease child.27 In the 10-year study period, people on plans where the employers’ bear 
the burden for enrollee’s health claims had an average enrollment for 84 months for rare 
diseases families and 72.6 months for all other families. This is consistent with other 
studies that found that rare disease caregivers are more likely to consider health insurance 
needs when making employment decisions.6,12 
Individuals with complex health conditions, such as rare diseases, often require 
more health care services. It is estimated that 10% of patients account for 65% of all U.S. 
health care expenditures and 1% accounted for 21.5% of all health care expenditures.28 
Attempts to limit healthcare costs have included initiatives to change behaviors or shift 
costs at the individual and systems level, including through managed care plans, 
investment in wellness programs, cost sharing, and the reduction of benefits.29–31 In a 
study of parents with children with genetic conditions, 68% expressed concern about the 
financial strain associated with getting health care and covering daily care expenses for 
their child.12  
Roughly 300 rare diseases have a Food and Drug Administration (FDA) approved 
orphan drug.32 There has been much criticism of the financial incentives and price of 




which were established by the Patient Protection and Affordable Care Act (ACA), found 
that coverage varied within and across states from 2-82% depending on the drug.37 Many 
of the drugs included cost sharing or utilization management provisions, including up to 
50% coinsurance until patients met the out-of-pocket maximums for the plan.37 There is a 
complicated balance between decreasing healthcare costs and meeting patient needs. To 
date, there have been no published studies that describe the rare disease health insurance 
experience in the U.S. through the perspective of the caregiver. The aim of the study was 
to qualitatively describe the rare disease caregivers’ experience with health insurance for 
their child living with a rare disease.  
Methods 
Study Design 
In-depth interviews were conducted with caregivers of individuals living with rare 
diseases. A qualitative study approach was identified to allow the subjects to guide the 
development of the themes and variables of influence to formulate an understanding of 
this experience.38 Grounded theory principles were used to conceptualize the study design 
and analysis.39 Two different conceptual categories were identified, a disease that has an 
FDA approved orphan drug and a disease without an orphan drug, to explore the 
properties that shape the patient and caregiver experience.  
Sampling and Recruitment 
Two diseases were chosen for inclusion in the study: metachromatic 
leukodystrophy (MLD) and spinal muscular atrophy (SMA). The heterogeneity of rare 
diseases makes it difficult to identify a “typical” disease. MLD and SMA were identified 




diseases have an identified genetic mutation, have varying degrees of severity within the 
disease, and the age of onset can vary based on the form of the disease.40,41 It is estimated 
that SMA affects 1 per 8,000 to 10,000 people worldwide.40 MLD is estimated to affect 1 
in 40,000 to 160,000 people worldwide.41 Both diseases have a patient organization that 
could assist with study recruitment.  
SMA and MLD both impact motor function. SMA is caused by the loss of motor 
neurons that impact muscle movement, especially proximal muscles.40,42 Some forms of 
the disease also impact the ability to breathe and eat. Diagnosis is confirmed through 
genetic testing and SMA is one of the core conditions on the recommended uniform 
newborn screening panels.43 In 2016, nusinersen was approved by the FDA to treat 
SMA.44 Clinical trial results found that the nusinersen group had a higher percentage of a 
motor-milestone response (37 of 73 participants), compared to the control group (0 of 
37). The nusinersen group also had a higher likelihood of overall survival (hazard ratio 
for death, .37; P=.004).45 Other disease management focuses on symptoms or 
management of specific health issues.46 
MLD leads to the destruction of white matter in the brain which causes 
progressive deterioration of motor skills and intellectual functions.41,47 Additional 
symptoms can include loss of feeling in extremities, paralysis, blindness, hearing loss, 
seizures, and the inability to speak; over time an individual loses awareness of their 
surroundings. Diagnosis is made through a medical evaluation and lab tests. A newborn 
screening pilot study is currently underway in Washington State.48 Stem cell 
transplantation may be appropriate for some patients and other treatments focus on 




Individuals were eligible to participate in this study if they were at least 18 years 
of age, a legal resident of the U.S., and the medical or legal guardian of a living 
individual diagnosed with SMA or MLD. Recruitment messages were provided to patient 
organizations that represent one of the diseases and sent through their email and 
Facebook pages in September 2018-January 2019. Messages reached roughly 7,200 SMA 
and 600 MLD families. Snowball sampling techniques were used to recruit additional 
MLD participants. Interested participants were sent to a study recruitment screening 
questionnaire to establish their eligibility and provide contact information. Individuals 
provided initial informed consent and then the primary researcher contacted individuals 
through email to set-up a time for the interview. Additional informed consent was 
provided verbally prior to beginning the call.  
Ethical human subjects approval was obtained from the University of 
Massachusetts Amherst Institutional Review Board. All participants received an informed 
consent information sheet and provided verbal informed consent prior to the start of the 
phone interviews. Data collection methods and research procedures were clearly 
documented and findings were considered to be an accurate and truthful reflection of the 
experiences of parents with a child with a rare disease.  
Data Collection 
Thirty-two individuals completed the screening questionnaire and 15 completed 
an interview. The other individuals did not respond to the emails to set-up a time to 
complete the interview or became unresponsive while trying to set-up a call. Calls were 
made to an individual’s phone using Skype, a conferencing software, as in-person 




by the primary researcher who has extensive professional experience with the rare disease 
community. Calls lasted an average of 29 minutes. An interview script (Appendix G) was 
developed prior to the interviews based on the key areas of interest for the study and the 
prior literature. As the interviews progressed, relevant follow-up and probing questions 
were used to gain additional insight. Interviews were then transcribed by a professional 
transcription service. Transcripts were read and compared to the original recordings by 
the primary researcher to ensure accuracy. Recruitment ended when the researcher 
believed data saturation had been reached; no new themes were emerging from the data 
and no new codes were needed for additional interviews.49 
Data Analysis  
Interview transcripts were analyzed using NVivo 12 software using both open and 
axial coding.50 Broad a priori codes such as “cost sharing” and “navigation” based on the 
categories of questions were created prior to the interviews. Coding was completed by the 
primary investigator in sections, refined, and organized into thematic categories. A 
codebook was created and discussed with a research assistant hired to work on the 
project. The research assistant independently coded one of the transcripts and then side-
by-side comparison was performed and there was discussion for any differences in the 
codes. This process was completed for a 2nd transcription and only minor differences 
arose, about 15% difference. The research assistant completed two final transcriptions 
and the side-by-side comparison showed near identical coding, roughly 5%, the 
differences were based on the inclusion of a few contextual words or phrases before or 
after the statements of interest. The researcher also utilized peer debriefing to discuss the 





Participant Characteristics  
A total of 15 parents (14 mothers and 1 father) participated in the study. Four 
parents had children with MLD and 11 parents had at least one child living with SMA. 
The median age of participants was 37. The median age of their children was 6 (birth 
years 1997 to 2017). Six of the participants were diagnosed the same year they were 
born, the longest time to diagnosis was 4 years. Individuals lived in the South (6), North 
(3), Mid-West (5), and West (1). For patient privacy, only the child’s initials are reported 
and quotes include the state of residence and child’s diagnosis. 
Every child had healthcare through at least one parent’s employer, eight 
participants were the primary policy holders. Eight patients were also double or triple-
covered through a public insurance program such as Medicaid (6) or the Children’s 
Health Insurance Plan (2). Two were on a Medical Assistance Program through their state 
or county, three were currently receiving additional services through their Early 
Intervention Programs, and four had participated in EI until their child aged out. One 
child was on Medicare. Most individuals did not differentiate between their public and 
private insurance experience and some commented that they were not aware of the 
specifics between the plans or what was covered under what plan mechanism.  
Model 
The Rare Disease Caregiver Health Insurance Experience Model (Figure 3) was 
created by the principle investigator to contextualize the experience as described by rare 
disease caregivers. The model was then shared and furthered refined through 




include demographics, location, employment, and the patient diagnosis. Emotional 
factors such as uncertainty, urgency, and responsibility also impacted decisions and 
involvement. Health literacy was a product of individual factors and evolves over time 
as an individual navigates the system and identifies strategies to successfully engage 
insurance companies. Established external factors of accessibility, availability, 
acceptability, and healthcare quality impacts an individual’s opportunity to obtain 
insurance. Politics was added to reflect the importance caregivers placed on the impact of 
political decisions, such as protections for preexisting conditions. An individual’s 
potential involvement in the insurance process was signified by the lines with a heavy 
border. Emotional and knowledge support was provided by external forces throughout 
the process. 
Obtaining, interacting, and accessing coverage decisions are where individuals 
encounter obstacles. Obtaining insurance can be complicated by the options available 
and whether an individual qualifies. Interacting with the insurance company requires 
complex documentation, redundancy in reauthorizations, time, and can result in 
incomplete information or being bounced to multiple sources in the company.  Accessing 
can result in approval of claims, coverage questions between multiple insurers, and costs 
to the patient. Individuals may dispute these claims, requiring further interaction. 
Coverage decisions may require the individual to access outside financial assistance. The 
result of this access can impact the health outcomes for the child, either improvements 
or medical setbacks, which can change the way an individual interacts with the system. 
The results of this process and the child’s health impacts overall satisfaction. 





Health Literacy  
Individuals showed high health literacy by identifying clear strategies related to 
how they navigate healthcare. Some people had confusion around the health insurance 
documentation, such as the benefit descriptions and explanation of claims. Most had 
identified strategies to get the information they needed, but most still found it challenging 
to navigate on their own, even if they were part of the health system.    
I mean, I am far more comfortable than the average person. I’m a physician myself. 
Although, I have still found it to be overly complicated and difficult, despite the 
years of, you know, training in the system. (SMA, TN) 
There was a strong sense that navigating insurance correctly was a necessity. Some 
people wanted more help in finding information, while others did not believe clearer 
answers existed or that insurance was willing to provide them. Individuals spoke about 
the iterative process of learning the system and piecing together information over time.  
You know, we have talked to a lot of organizations and individuals over the course 
of her 11 months of life, but I think it has really fallen to us to educate ourselves. 
So, I mean, we’ve probably talked to 50+ people from advocacy groups, to 
disability coalition, to lawyers, to case workers, to social workers to, you know, 
political advocates, and I think each person has provided us with a little piece of 
information, but it’s kind of remained up to us to sort of figure out overall how to 




Involvement and Support 
Parents felt obligated to research their needs, chase down answers, and secure the 
authorizations directly from the insurance plan. People described keeping detailed notes 
of everything they were told by insurance agents. Often, they were reliant on medical 
professionals or other advocates to write letters for medical necessity or to get them 
started in the right direction for securing approvals of healthcare services. Sometimes this 
help came from within the community of families living with the disease, such as an 
SMA specific health insurance Facebook page. In some cases individuals would 
passively wait for claims to move through the system and “resolve themselves”, but most 
individuals indicated they needed to be vocal and involved for success.  
Yeah, so I kind of go into mama bear advocate mode. [laughter] And I don’t like 
going to that place, because it usually means I have to be very assertive. I always 
try to be super polite, so I hate having to be aggressive with them. But it usually 
means I have to do a lot of follow-up calls or I have to do a lot of follow-up 
paperwork. (SMA, CA) 
Many individuals tried to pre-plan their short and long-term care health needs and 
work with insurance to see what might be covered in a specified timeframe. The purpose 
was to get needs met quickly and anticipate potential denials or reauthorization periods to 
limit disruptions in care. Caseworkers within the insurance company were sometimes 
provided proactively, while other individuals requested one. Caseworker quality was 
described as highly variable but improved if the caseworker stayed with the family over 
time. Individuals felt that caseworkers had the potential to help navigate the terminology, 
documentation, or indicate areas for saving money. Some individuals felt this was 
successful to help them plan, but many others felt that insurance would not provide clear 




So, and we did have a case manager with my husband’s insurance, I don’t know if 
we triggered some sort of, you know, like, high cost flag or something. 
[laughter]… And I never found that person terrible useful. You know, like, I had 
these conversations and I explained our situation, and she just really couldn’t 
provide me assistance in any sort of useful way. So, I liked the idea, but it didn’t 
turn out to be what I hoped. (SMA, IL) 
You know, it’s not something you’d notice the next day, like, some service kind of 
message or something like that, it’s just we would be missing out, and we 
wouldn’t know what we’re missing out on or what’s available down the line. 
(SMA, NY) 
Emotional, logistical, and knowledge-based support was proactively sought by 
parents or provided at many points in the process of navigating insurance. Disease 
specific organizations, disability organizations, or social services agencies were often 
seen as a valuable starting point for support and knowledge. Providers were also seen as 
supportive knowledgeable resources. Conversely, providers could be a barrier if they did 
not believe that a test or treatment was necessary. Benefits managers or members of the 
leadership team, such as Presidents, at the place of employment provided guidance and 
intervened to get benefits on behalf of some of the families.  Most individuals spoke 
about the importance of peer support to find others who understood their experience and 
could provide valuable insight on navigating insurance. Often this came from connections 
made through organizations or social media, especially Facebook.  
There was at least one time I remember specifically, where I was receiving 
incorrect information from our insurance company. I went online. I was put on 
hold, because they were trying to figure things out, and I went online, and I said, 
“Hey, who here has this insurance company and was told that?” And literally 30 
seconds later, another mom wrote in to say, “We do. This is what I was told, and 
this is what you need to tell them.” So by the time I got off hold, they were like, 
“Here.” I told them, “Here, this is what it is. No.” I was like telling the insurance 





All individuals stated their child had consistent insurance coverage. Some 
participants had difficulty obtaining secondary insurance or described the process as 
daunting and time consuming. Individuals described both positive and negative aspects of 
state specific eligibility criteria or benefits. Secondary insurance, such as Medicaid, was 
seen as critical to unlocking access to some forms of care, including nursing services and 
therapy. Only MLD caregivers discussed their lack of a diagnosis as a barrier to being 
able to qualify for secondary medical insurance, but individuals from both disease groups 
discussed challenges.  
Almost every single state in this country has a waiver that allowed medically 
disabled children to get on the state Medicaid system, so that they can get access 
to all of those services, regardless of parental income, and our state does not have 
that, so that has been incredibly difficult for us, and has been a major barrier in 
getting her care, you know, nursing, and some of the equipment that is only 
covered by Medicaid, it’s not covered by private insurance. (SMA, TN) 
Employment was a major factor in obtaining insurance and many people felt 
limited in their coverage based on the options available to them through their employer. 
The scope of benefits was also attributed to the size of the employer, especially in 
covering unique services or treatments.  
That might work for, like, a Walmart, where it’s spread over 50,000 employees, 
but the [organization] that I work at has 300 employees, so if you added a rider 
saying, “Nursing for SMA is now covered,” and everyone’s premiums go up $5, 
they all know I am the one using that. (SMA, NY)  
Their child’s health insurance needs were cited as a determining factor when 
considering employment decisions and contributed to job loss fears. One individual spoke 
about fears of repercussions for being “too costly”, despite the legal ramifications of 
discrimination.  
Insurance will always be a determining factor of taking on a new job, because if 






The time needed to interact with insurance and processing claims was one of the 
most prominent obstacles. One source of delays in approvals or claims was related to the 
interplay between multiple insurers or providers incorrectly submitting claims to the 
wrong insurer. Getting through the automated systems and first tier customer service 
representatives to get accurate information was especially complicated with the realities 
of life.  
And so, especially if you’re trying to manage – you have other children and you 
work and you’re trying to keep a household and what not, it’s hard to sit on the 
phone for 30 minutes waiting for someone to help you, and then, you may get 
redirected five times. (SMA, CA) 
Many of the SMA parents discussed the wait time associated with the FDA’s 
approval of nusinersen and the additional time to get access to the drug through 
insurance. The sense of urgency for the health benefits of nusinersen were palpable, one 
individual even structured her birthing plan around getting her child a Social Security 
number, which is necessary for health insurance enrollment paperwork, to access the 
nusinersen as soon as possible. Individuals in this study whose children received 
nusinersen within a few days of being born, stated their children were essentially 
asymptomatic and did not require any specialized care beyond nusinersen.  
A lot of it came down to the cost because it’s so costly per injection. U of M 
wasn’t just going to give her the treatment and figure out the billing later and 
insurance was going to take their sweet time looking at it, so like we're just kind 
of stuck somewhere in the middle. And 30 days is a long time when your child is 
waiting for a life-saving medication.  (SMA, MI) 
Some people believed that they could interpret their benefits themselves, but most 
felt they needed help to decode the information. When individuals tried to contact the 




could provide an answer and many cited times when they felt that they received different 
answers from different people. The lack of transparency in tracking claims and the 
inconsistency in approvals was a large obstacle. Correctly submitting documentation was 
described as a team effort. Providers submitting claims to the wrong insurer or incorrectly 
submitting claims using the wrong code could result in claims sitting in limbo for months 
or denials. Certain treatments, referrals, and equipment required reauthorizations, the 
repetition to continually prove the same medical necessity or on-going care needs was 
seen as time-consuming and as a disruption in successful care routines.   
At least the specialists that she will need for the rest of her life, it would be very 
nice if we didn't have to get referrals all the time and then sort of deal with, “Oh, 
you know, this appointment wasn't covered under the years’ worth of referrals 
that we sent in that time.” (MLD, NY) 
For example with M’s Synagis injection last year, we waited like 2 months for 
insurance to approve it, and I got a letter like two days after Christmas they 
approved it, and then the new year started so we had to get a new approval… She 
doesn't have something that's just going to get better or go away. She’s always 
going to have it; so I just don't know why we have to keep running through the 
same circles for the same thing. (SMA, MI) 
The insurance companies’ comprehension and understanding of the medical 
situation seemed inadequate to most participants. This was related to both a 
misunderstanding of the medical needs and the complete picture of other care needs, such 
as equipment or services to help with day-to-day living. Due to the lack of knowledge of 
the disease, parents wanted insurance to try to understand their case history or defer to the 
medical professionals related to their care needs when making coverage decisions.  
So, for example, she has to be on continuous pulse oximetry monitoring, which we 
were denied multiple times, getting that piece of equipment, until our doctor wrote 
for oxygen, and she doesn’t actually need oxygen. In fact, that’s kind of 
contraindicated actually in SMA, because the problem is not oxygen delivery, it’s 




oximeter to monitor her oxygen level, you know, in her blood, and her adequacy 
of ventilation until she was written for oxygen (SMA, TN) 
For her, you might need a drug that is proven for cystic fibrosis, but we know for 
a fact that she has some of the same lung issues, but we may not be able to get the 
insurance to cover that equipment or that drug because we don't have the 
background that says, "Oh yeah, they will work for MLD too." (MLD, MN) 
People wanted to be treated with a sense of respect and felt that they were being 
treated as if they were trying to “game” the system, when individuals just wanted to 
provide appropriate care for their child. When they did not feel heard, respected, or if 
there were inconsistencies in what they were told, it often eroded trust and further 
establish a need for the parents to be vigilant and fight. Many people used what they 
learned as part of the run-around to devise strategies to get faster or more accurate 
answers in the future.  
The left hand doesn’t know what the right hand is doing, and that makes it really 
tricky to navigate, because, you know, it puts more pressure on the parents or the 
caregiver to do their due diligence, where I feel like it shouldn’t necessarily be all 
on us to do it. (SMA, TX) 
Accessing 
Individuals experienced the greatest barriers to coverage for equipment, nursing 
care, therapy, and out-of-network providers. Individuals who were aware of tiered-
financing schemes indicated their providers were always on the highest tier where they 
would need to pay the most out-of-pocket. Seeking out of network care was discouraged 
by insurance, but many caregivers expressed the frustration of not being able to see out-
of-network disease specialists or go to the specialty centers where children could benefit 
from targeted knowledgeable care.  
We live on Long Island in New York, and he wanted – it was recommended that 
we go to Columbia Children’s Hospital, where they have an SMA clinic, but 
originally, we were denied coverage there because it was out of network, and 




home… they weren’t going to cover us going to Columbia, where we would argue 
that there’s not any other SMA specialists out here. (SMA, NY) 
Nursing care was a critical support for families. Finding the mechanism to get 
nursing care was often described as a time-consuming challenge, especially if people 
could not qualify for Medicaid. Nursing companies were often critical in helping 
caregivers navigate the coverage. A good nurse was described as being invaluable to a 
family and often went above and beyond in providing guidance and support, but there 
was high turnover.  
We only had one hour of a consultation nurse. That nurse stayed for three hours, 
stayed two hours on her own time, because she felt that we were in kind of a dire 
situation and didn’t have any of the home care set up, because we, you know, 
didn’t know how to set up our home. Nobody took us—nobody met us at home. So 
he went home without insurance covering private-duty nursing, and we had no 
nursing coverage, and we were expected to stay awake all night while my son 
returned from the hospital, and that did not end well. (SMA, MD) 
Therapy was described as expensive and critical to helping the child achieve the 
best mobility and health outcomes. Many companies had caps on what is covered by 
insurance, but the terms of coverage were often unclear. Multiple people spoke about 
trying to get clarity on the number of allotted hours only to be quoted wrong information 
and losing access mid-year.  
If you’re making, like, huge gains, which is good, but it, would be, something, 
like, $28,000, which I couldn't afford. Because, it says here, physical, speech, 
occupational therapy, “Subject to specialist’s office, visit copay,” which is $0, 
“And 90 visits per calendar year.” So, for me, I should be able to go to wherever 
we want for 90 visits a year, but I don’t really know where I can go, and for what. 
(SMA, NY) 
Every year, we run out of PT hours, and we run out in October, so we have a hard 
limit on our insurance, and every year, a nurse case manager that’s on our case 
tells us, “Oh, if you get a doctor’s prescription, you can increase it.” We say 
every year, “No, we can’t,” and then we spend another 90 minutes on the phone 
between our physical therapy gym and the insurance company. (SMA, MD) 




the scope and total cost of their care needs. There was a split between individuals who 
just referred to “bills” and those who can recite their entire paradigm of premiums, 
deductibles, copays, and coinsurance. Some of these fees were covered as a perk of 
employment or through secondary insurance programs. Some individuals had out-of-
pocket maximums for the year. Those who had deductibles spoke about how quickly they 
met them.  
And then we have like a per-person ones, like M's is 500 and she meets that within 
like 30 seconds in the new year so. (SMA, CA) 
The cost of equipment, drugs, therapy, and out-of-network services were 
described as the most expensive parts of care. These types of services often had cost-
sharing mechanisms, but the patient’s portion was still quite large.  
So, you know, 20% – or, I guess it’s 10% drug. But anyway, you know, a 10% 
copay on a $150,000 per year bill is, like, prohibitive for most people. (SMA, TN) 
Different values contributed to different expectations about what should and 
should not be covered, especially around equipment and quality of life supportive 
technologies, such as powerchairs and adaptive beds. Some individuals were narrowly 
focused on specific medical costs, while others looked at the full paradigm of care and 
support. Many expressed that if a doctor indicated that something was medically 
necessary, families should have an affordable way to access it.  
Again, I know there are like private groups that you can go on funding and you 
can do social funding, but things that like are clearly medical necessities in order 
to be able to navigate the home and reach the home and go to the doctor's 
appointments, for example, seem like they should have better coverage. (MLD, 
MA) 
Insurance was described as one piece in the larger financial structure, but timely 
complete information was necessary for long-term planning. Almost all of the SMA 




company’s copay assistance program. Early intervention was described as a key safety 
net program for individuals to get started, but there was concern about what would 
happen when the child aged out after 3 and this assistance ended. The expectation is that 
schools will provide services and equipment. The variability of school resources, 
knowledge, and capacity to support students was identified by the parents. An individual 
often needed to decide when to utilize outside sources of assistance, such as grants or 
fundraisers.  
And I really think that when you look at someone's care needs you know 
insurance is one part of it but it's really like trying to understand all of the 
benefits including insurance that they are entitled to and how all of those pieces 
need to work together. (SMA. MN) 
A few individuals spoke about how they have not accessed any other sources of 
financial assistance due to time, a sense of greater future need, eligibility, or they felt that 
others required the assistance more. Many people reflected on how they did their best to 
contribute their fair share and to cut costs by repurposing supplies or using equipment 
shares, but they wanted insurance to understand the importance of the needs they did 
submit.  
Now, I am trying to get some equipment for her mattress and I am just trying to 
get it paid for with the proper paperwork signed and everything to get it through 
and it is almost like I feel if I did the financial analysis on how much it costs to 
take care of a wound, they would certainly rather pay for the mattress, it is 300 
bucks instead of the $3000 that it is going to cost if I have to put her in the 
hospital time and time again. (MLD, MN) 
A few individuals spoke about shifting formularies, gatekeeping requirements, 
networked providers, and benefits that sometimes changed how the individual could 
access care. Sometimes these changes would be related to eligibility shifts, such as a 
provider who was included in Early Intervention, but out-of-network when the child 




might only be uncovered when individuals received a bill or were outside of their plan’s 
scope of coverage.   
The state of Illinois doesn’t really care that she’s out of network, but then, when S 
turned three, we have to deal with the insurance and her billing and stuff directly. 
(SMA, IL) 
Many people discussed the concern about the health consequences of the delays 
or denials of the insurance company, especially the potential for worst health outcomes or 
lost opportunities, such as clinical trial participation. People spoke about how the 
coverage they could access would impact their life decisions, such as having more 
children. Many expressed a sense that things were not fully in their control and they only 
had so much bandwidth to continually fight. The political climate and fears of losing 
protections for preexisting conditions weighed heavily on many. Only a few people spoke 
directly about their own mental health.  
Satisfaction and Health Outcomes 
 When asked if individuals were satisfied with their insurance, many said yes, 
despite describing challenging experiences. One respondent stated, “That’s kind of a trick 
question.” Those who were most satisfied had decent benefits or had overcome a large 
obstacle with coverage. Some people were very distrustful, but most expressed a sense 
that they wanted to work better with the companies to find the best way to balance their 
child’s needs, doctor’s recommendation’s, and cost-savings.   
It can be a nightmare if the right people aren’t in place to monitor it… Yeah, so 
because everything is pretty covered for her, and we, again, knock on wood, are 
pretty healthy, there’s not a lot of – I don’t feel that I am having to follow up with 
insurance companies or, you know, ask for things to get taken care of. (MLD, TX) 
It shouldn’t be about, “Oh, sorry, you can’t have this because it’s too expensive.” 
Well, but that’s what the patient needs. So, if that’s what the patient needs, find a 




A few reflected on the importance of taking care of each other and how their 
experience has impacted their individual value sets. Individuals also looked at their own 
privilege related to education, support, and the severity of their child’s condition when 
reflecting on their experience compared to others. This sometimes resulted in not 
accessing certain financial resources or finding ways to give back to others in the 
community in whatever way they could.  
And it's like basically, I think you know could be a part-time job for someone. And 
so, for people who perhaps are not native English speakers or who don't have a 
level of education that allows them to sort of navigate through these systems or 
don't have the time to be on the phone for you know 10 hours a week on hold or 
whatever, I think really is a disservice and kind of a shame. (SMA, MN) 
When looking at what changes caregivers most wanted to see, many people spoke 
about making the process more user friendly, decreasing the time it took to interact and 
get approval answers, and reducing the need for reauthorizations for on-going needs. 
Communication was a consistent theme including a desire for a clear line of direct 
communication, greater transparency, and a shift to more consumer-focused care. People 
wanted to be treated humanely and with an understanding that they are just trying to take 
care of their child.  
It goes back to walking around with, you know, in somebody else's shoes and 
trying to figure it out. It is not like we are trying to take advantage of anybody 
when we have kids with rare genetic illnesses. It is very difficult. (MLD, MN) 
I guess I just wish, like, the answers were easier to find, and they were more black 
and white, like, as if it was more like a puzzle, and felt like, “You know, isn’t this 
the point of having a job and health insurance, so that when you have something 
you need, like, you’ll get it?” (SMA, VA) 
I mean, I hate it, but it has to be done, because we can’t afford to not have it be 
done right, so we just have to continue to keep this documentation of every call 
and every time and what they said, because I feel like I’m more organized than 
they are, and I feel that I have to be, because my daughter’s definitely worth it, so 





The purpose of including MLD and SMA was to explore the potential differences 
in the presence of an orphan drug for patients accessing medical care. However, these 
preliminary results indicate limited differences in the caregiver experience based on the 
availability of an orphan drug. This is consistent with previous findings that rare disease 
care needs are largely similar despite disease differences.6 SMA patients with early 
access to nusinersen, did not experience many further healthcare coverage needs, which 
was different from their peers whose children still required complex care needs. Both 
SMA and MLD parents had to fight with insurers to gain access to services and products 
seen as medical necessities. The MLD care needs are less established, which often 
required additional justification to ensure insurance coverage.   
Parents and medical professionals often were looking at long-term needs and 
outcomes, while insurance was more focused on more immediate utilization controls 
aimed at reducing access to expensive drugs and services. This applied to the medical 
pay-off of certain equipment in preventing hospitalizations or medical complications and 
the approach for finding an MLD diagnosis; test-by-test vs whole genome sequencing 
which could provide a broader scope of genetic data. This is consistent with studies that 
indicate that diagnosis can take years.8 The negotiation between insurance company and 
patient interests will likely create inequities based on an individual’s health literacy and 
overall access to knowledgeable providers. As a society, we must decide how we believe 
these negotiations should go and what entities we believe should be driving decisions.  
Managed care models of insurance rely on patients using in-network care. 




locations9 and may only have a handful of experts or specialty centers, which are often 
organized regionally or nationally.10 Patients may need to seek care outside of the 
insurer’s negotiated networks of providers. We must find a way to balance these 
competing needs to allow individuals to access disease experts, without unduly burdening 
patients with greater out of pocket costs. Private insurance companies are often only 
temporary stewards of an individual’s health as individuals are assumed to change plans 
every few years. Long-term savings, such as through supportive technologies, may not be 
as important as the year-end bottom line. However, with complex conditions small 
setbacks can become incredibly costly and disruptive to the health of the child and the 
life of the family.  
Currently, there are assumptions related to the care paradigm that most people 
will navigate, including logical places to gain access to certain services based on 
demographic factors. However, if a state has exclusions to secondary insurance or if an 
individual has more complex needs then can be addressed at the site (such as a school), 
the system is not equipped to adjust. Complex care cases have few options for recourse 
within the system and may toil in limbo or fall through the cracks, unless caregivers can 
devote the time and energy to fight for needed services.  
A few individuals interviewed commented on structural changes or unique 
providers that were seen as beneficial. One had a complex care provider through the 
hospital that was able to serve as the gatekeeper and primary navigator for other points of 
care but was equipped with the specific knowledge of complex care needs and available 




for the Medicaid program in their state, which from their perspective made the process 
when accessing services more seamless.  
Based on the interviews, policy changes or insurance company initiatives that 
could improve the experience of rare disease patients include establishing time limits for 
processing coverage decisions and increasing the transparency in the claims and 
preauthorization process. Allowing options for universal authorizations for certain 
domains of care or changing the frequency of the reauthorizations would also decrease 
the burden on families and medical providers to continually prove medical necessity. 
More research into the natural history of rare diseases and establishing medically 
recognized treatment guidelines would improve evidence-based care for patients, 
especially if insurance was required to provide coverage for the services necessary to 
follow those guidelines.  
Training insurance specialists that are familiar with complex and chronic care 
needs, are trained to review medical records, and can interface with this population in a 
respectful way, would also increase the overall experience for patients. It is unrealistic to 
expect insurance companies to become experts in every rare disease, but there should be 
a framework for assessing claims to make coverage decisions without unduly delaying 
progress or harming patients. Individuals who felt that there was someone at their 
insurance company who could intelligently answer questions, had far fewer complaints 
than those who did not.   
Our healthcare delivery system is moving towards centers of excellence or a 
centralized hub model of for specialist care, but our payment systems often require in-




Individuals with compelling needs to see an out-of-network specialist should have an 
opportunity to seek waivers from out-of-network care cost restraints or to seek expert 
opinions in a cost-effective way. This goal would be easier to achieve if health insurance 
companies were incentivized to invest in an individual’s long-term health outcomes. As 
the U.S. investigates single-payer healthcare options, which would likely integrate 
payment and delivery networks, we need to identify appropriate ways to make allocation 
decisions for the long-term health of an individual. Successful policy changes must 
include the patient voice to ensure that solutions for a sustainable healthcare system are 
flexible for adapting to evolving patient needs. 
Limitations 
The estimated MLD population is smaller, recruitment was more challenging as 
the disease organization infrastructure is less developed. Every MLD caregiver who 
participated offered to help recruit. This likely means that the MLD participants joined 
due to personal outreach and snowball sampling, where most of the SMA participants 
self-selected due to general recruitment messages. The SMA group also did not include 
any individuals who are not currently using nusinersen, the overall proportion of 
individuals on the drug cannot be determined, which makes it difficult to assess the 
impact of this representation. There is a limit on the amount of time caregivers can give 
and it is possible that we are missing the perspective of individuals who are in even more 
dire financial situations. Insurance status was self-reported and cannot be validated, but is 





Although, there was some geographic diversity, some states included multiple 
participants including Minnesota and New York. The study also put a large importance 
on equipment and therapy as these are key features in diseases with mobility issues, other 
rare diseases are likely to have slightly different needs, which may result in other 
unexplored challenges. However, we believe that the themes and the model provide a 
medically agnostic starting point to the overall caregiver experience. Finally, as a 
qualitative study the results could be subject to other interpretations, but this was limited 
due to the use of double-coding and peer-debriefing.   
Conclusion 
This study adds to the scholarly research and literature and has the potential to 
improve practice and policy. There are possible policy initiatives that could impact our 
payment and delivery systems that could greatly improve patient experience and 
outcomes. However, it is critical that the patient voice is represented in efforts to 
establish a framework for assessing and approving care needs. Parents with a child living 
with a rare disease are required to meticulously track insurance in order to maximize 
benefits. They are often asked to navigate difficult decisions to balance medical needs 
and financial stability. Individuals are often grateful for a supportive network of peers 
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MEDICARE PART D ORPHAN DRUG EXPENDITURES 
FROM 2013 TO 2017 
 
Background 
Rare diseases  
In the United States, a rare disease is a condition that impacts less than 200,000 
people.1,2 An estimated 30 million Americans are impacted by one or more of the roughly 
6,500 identified rare diseases.3 The diseases are clinically heterogenous and an estimated 
60% are genetic in origin. Many of the conditions have insufficient research resulting in 
undefined clinical guidelines, limited treatment options, and inadequate knowledge 
among some healthcare providers.4–10 Individuals living with rare diseases often feel 
isolated and can face challenges finding an accurate diagnosis and treatment plan.8,11  
Orphan drug coverage and expenditures  
Orphan drugs are products designated for the treatment of rare diseases. The 1983 
Orphan Drug Act (ODA) provides economic incentives for the research and development 
of orphan products including 7-year marketing exclusivity, fee-waivers, and grant 
opportunities.2 Companies developing a product submit an application to the Food and 
Drug Administration (FDA) to establish eligibility for obtaining an orphan designation.12 
Drugs are eligible if they are intended to treat a disease that affects fewer than 200,000 
people in the U.S. and there is no expectation of recovering the research, development, 
and marketing costs from U.S. sales of the drug. This process can occur at any point 




Once there is evidence related to the safety and efficacy of the drug, the company 
submits a marketing application to the FDA. The FDA approves the drug’s indications, 
the identified uses for the drug. Indications are based on the clinical trial information and 
the marketing application materials. The indication is often narrower than the orphan 
designation and may only include a subtype of the disease or a specified patient 
population.12 Between January 1983 and August 2018, 503 drugs were approved with an 
orphan indication. Of those drugs, 394 (78%) were only approved for the orphan 
indication, while 109 (22%) also had a non-orphan indication.13  
There has been criticism related to the price of orphan drugs.14–18 Using 2017 
invoice prices, the median annual cost for an orphan drug was $46,800 per year and the 
mean was $87,319.13 Of the 374 orphan drugs that were on the market in 2017, 301 
(80.4%) had an annual cost of over $6,000 and 73 (19.5%) of the drugs had an annual 
cost per patient of less than $6,000.13 Of those, 109 (29.1%) were oncology products with 
an annual cost of over $6,000 which represented 40.8% of all orphan sales.13 There are 5 
orphan drugs (1.3%) that are priced over $500,000 per year, which contributed to 1.8% of 
total orphan drug spending.13 The average sales for the 50 highest-selling orphan 
products was $639.5 million and the next 50 highest selling products averaged $139.5 
million in 2017.13 These costs may not reflect what an individual or a payer actually 
spends based on the availability of medication assistance programs or coupon programs.  
Patients are experiencing high healthcare costs, for drugs and other medical costs. 
A nationally representative sample of U.S. adults found that 17.9% of families and 23.3% 
of individuals reported having problems paying for medical bills in 2016.19 A Gallup poll 




about healthcare costs and an estimated 15 million individuals deferred or skipped 
recommended medicines due to costs.20 Studies that focused on families living with rare 
diseases or genetic conditions also report concerns related to financial stress.7,21 In 
oncology, the term “financial toxicity” has been used in the healthcare literature to 
describe the impact of the financial burden of treatment on a patient’s overall 
wellbeing.22–25 Having insurance can help decrease costs associated with drugs, but there 
is a high degree of variability in orphan drug coverage across insurance plans. Insurance 
access to orphan drugs through Health Insurance Exchange plans established through the 
Patient Protection and Affordable Care Act (ACA) found that insurance coverage varied 
within and across states from 2-82% coverage depending on the drug.26 
In the research literature, orphan drugs are sometimes considered a subsection of 
specialty pharmaceuticals. Specialty pharmaceuticals tend to include biologic and 
injectable agents and are often used for complex conditions, including cancer and some 
conditions that are considered rare.27 However, there is not an agreed upon definition for 
specialty drugs. One definition is based entirely on the cost of the drug; for 2019 one 
definition is a drug that costs at least $670 per month.28 Another definition requires that a 
drug meet a certain number of cost, delivery, and medical factors to be considered a 
specialty drug.13,29 Specialty drugs often require prior authorization or impose quantity 
limits.30 Information about specialty drugs can help inform orphan drug research.  
Three studies have looked at the total orphan drug expenditures in the United 
States. In 2017, total drug sales in the U.S. based on corporate sales data were $451 
billion for pharmacies, clinics, hospitals, and healthcare providers; with $43 billion 




orphan specialty drugs.13 A 2017 study found that orphan drug spending was $36 billion 
(7.9%) of the total $450 billion drug sales in 2016.13 The study also found that orphan 
drugs contributed $14.6 billion of growth in spending from 2011 to 2016 while non-
orphan specialty drugs saw $74.6 billion in growth in the same time period.13 In 2013, 
orphan drug spending totaled $30 billion (8.9%) of total pharmaceutical expenditures in 
the U.S.31  Oncology drugs represented $12.22 billion (40.7%) of the total orphan drug 
expenditures.  
Internationally, orphan drug expenditures represent less than 6% of total 
pharmaceutical expenditures. In 2007, a study of 5 European countries found that the 
percentage of orphan drug spending as a percentage of total drug spending was 1.7% in 
France, 2.1% in Germany, 1.0% in the UK, 1.5% in Italy and 2.0% in Spain.32 More 
recent studies found that the orphan drug percentage of total pharmaceutical spending 
was 5.6% in Canada in 201333, 2.7% in Sweden in 2013,34 3.2% in France in 2013,34 
1.9% in Belgium in 2008,35 4.2% in the Netherlands in 201236, and 3.3% in Europe in 
2010.37   
Medicare Part D 
Medicare Part D is a prescription drug coverage plan that was implemented in 
2006 and is administered by the Centers for Medicare and Medicaid Services (CMS).38 
The program provides pharmaceutical coverage for individuals enrolled in Medicare. 
Medicare is a health insurance program that was established in 1966 for the elderly and 
was expanded to individuals with permanent disabilities in 1972. In 2018, 43 million 
people were enrolled in Medicare Part D.28 The majority of individuals (58%) are 




Medicare Advantage prescription drug plans (MA-PD). The Low-Income Subsidy (LIS) 
program provides premium and cost-sharing assistance for roughly 12 million (39%) of 
Part D enrollees.28 Dual eligible individuals who receive benefits through Medicaid and 
Medicare, are required to participate in Part D.  
The majority of individuals enrolled in Medicare Part D are over the age of 65, 
but 8.6 million people (14.4%) are under the age of 65 and qualify due to a long-term 
disability.39 An individual who has received Social Security Disability Insurance benefits, 
based on a long-term physical or mental impairment that will last for more than 24 
months, can become eligible for Medicare. If an individual has end-stage renal disease or 
amyotrophic lateral sclerosis, the individual can begin receiving benefits without the 
waiting period.28 The Compassionate Allowances program identified a list of conditions 
that have already been evaluated to qualify as a serious disability, many of these 
conditions are rare diseases.40 The program was established to reduce the wait time for 
individuals with serious conditions to receive Social Security benefits.40  
Compared to beneficiaries over the age of 65, younger Medicare beneficiaries are 
more likely to be male (55% versus 44%), have lower incomes, and are more likely to be 
Hispanic or black.41 In 2012, 65% of younger beneficiaries had a cognitive or mental 
impairment, compared to 29% of beneficiaries over 65.41 A similar proportion of 
beneficiaries from both age groups reported having five or more chronic conditions, 31% 
for under 65 and 28% for over 65.41 Nearly 35% of younger beneficiaries are dual 
eligible for Medicare and Medicaid, compared to 10% of beneficiaries over 65. 41 




D plan and 55% qualify for the Part D LIS. Sixty-three percent of older beneficiaries are 
enrolled in a Part D plan and only 16% qualify for the LIS subsidies.41  
Medicare Part D has been credited with a decrease in total out-of-pocket 
expenditures for beneficiaries.42–46 After Part D implementation, there was evidence of a 
shift in drug expenditures from private insurance and Medicaid to the Medicare 
program.43,46 Some studies also showed a decrease in hospital admissions for individuals 
who were enrolled in Part D plans.47,48 Medicare beneficiaries can be subjected to high 
out-of-pocket expenditures through cost-sharing mechanisms and can find it difficult to 
identify the right plan for their needs.49 
Part D cost sharing mechanisms  
In 2019, there were 901 unique Medicare Part D prescription drug plans offered 
across the country, with at least 22 plans available in each state.50 The average premium 
for Medicare PDPs in 2018 was $41 per month and the average MA-PD was $34.28 
Deductibles were included in 45% of plans.28 Most of the plans included a formulary that 
lists the covered drugs under the plan. Formularies were required to include at least two 
drugs in each prescription class or category, the included drugs can change during a plan 
year.51 Cost-sharing differs across plans and drug types, with higher-cost sharing for 
brand drugs and drugs that were off-formulary.30 There can be considerable variation 
across plans, one study found that cost-sharing for a 30-day supply of 10 brand drugs 
could be between 2 to 14 times higher on a particular PDP compared to another.30 
Copayment and coinsurance rates in drug plans were established based on a tiered 





Once an individual on Medicare Part D has spent a certain amount of money, 
most plans require that the individual enter a coverage gap or “donut hole”.53 While in 
this gap, individuals pay a larger share towards drugs until the end of the plan year or 
until the catastrophic coverage amount is reached. In 2019, the coverage gap begins after 
an individual and the plan spend $3,820 on covered drugs.53 While in the gap, an 
individual pays 25% of the plan’s costs for brand name drugs and 37% for generic drugs. 
In 2019, an individual leaves the coverage gap and operates under “catastrophic 
coverage” after the person has spent $5,100 out-of-pocket.54 For the rest of the year, 
drugs are subject to 5% coinsurance. The ACA legislated the closure of the coverage gap 
and in 2020 an individual will be responsible for 25% of the costs for brand name or 
generic drugs while in the gap.55   
Part D access to drugs 
A 2010 study of Medicare Part D coverage of 99 orphan drugs found that each 
orphan drug was covered by 87% of MA-PDPs and 84% of PDPs.56 Four drugs were not 
listed on any PDPs, but all other drugs were covered by at least 50% of national plans.56 
There is higher coverage for national plans (86%) compared to plans that are only offered 
in certain states (77%). Within nonnational plans, 23% of drugs have low or no 
coverage.56 Of the covered drugs, 19 (20%) were covered by less than 50% of the 
nonnational plans. Of the covered drugs, 84 (88%) were on tier 4 or higher on at least one 
PDP and 28 (29%) were placed on tier 4 or higher by at least 75% of plans.56  
Drug approval can occur through traditional channels or accelerated approval 
pathways.57 A study of FDA approved therapies that used novel approval pathways 




designation.58 Overall, 129 (90%) of the drugs in the study were covered by at least one 
Medicare plan, 93 (65%) drugs were covered by at least half of the plans, and 22 (15%) 
were covered by all of the plans within one year of approval.58 Three years after the 
approval of the drug, 140 (97%) were covered by one plan, 112 (78%) were covered by at 
least half, and 40 (28%) were covered by all of the plans. The median proportion of plans 
covering the orphan drugs in the study was 62% (IQR=43-92) at one year post-approval 
and 79% (IQR=66-100) at year three.58   
Part D expenditures  
The average per capita spending for Part D drugs for a beneficiary under the age 
of 65 is $3,817 compared to $1,159 for an individual over the age of 65.41 A study 
comparing the spending patterns for people who had LIS discounts and those that did not 
found that individuals who received the LIS discounts had total Part D expenditures of 
$1,887 compared to $1,341 for individuals that did not have LIS or another form of gap 
coverage.59 Additionally, the individuals with LIS paid an average of $148 out-of-pocket 
compared to $570 out-of-pocket for individuals without supplements. Of the total 
expenditures, for individuals with LIS 27.6% occurred after the individual reached the 
coverage gap and for individuals without supplements to help with drug costs, 16.9% of 
expenditures occurred after the gap.59 Prior authorization was required for coverage on at 
least one Medicare Part D PDP plan for 80 (84%) orphan drugs and 33 (35%) orphan 
drugs were required to have prior authorization by at least half of the PDPs.56   
No study has investigated all orphan drug expenditures in Medicare Part D, but 
studies have looked at expenditures and out-of-pocket costs for categories of drugs that 




drugs. Multiple studies have been conducted to look at specialty drug spending trends. In 
a study of specialty drug spending in 2007-2011 for a 20% random sample of all 65+ 
Medicare beneficiaries, specialty drugs accounted for $7.6 billion in total pharmacy 
spending in 2007 and $10.2 billion in 2011.27 Per beneficiary spending increased from 
$2,641 to $8,976 in the study period. This represented 6.7% of total drug spending per 
beneficiary in 2007 and 9.1% of spending in 2011.27  
A study of Medicare beneficiaries from 2007 to 2011 found that spending on 
specialty drugs per beneficiary increased in almost all therapeutic areas and significantly 
increased in oral cancer agents ($17.5 in 2007 to $40.99 in 2011) and immunomodulators 
($15.6 in 2007 to $32.29 in 2011).27 In 2010, the out-of-pocket burden for specialty drugs 
decreased by 26%, which the authors theorize is related to a reduction in the cost-sharing 
burden while in the donut hole.27 A Congressional Budget Office (CBO) report on 
specialty drug spending in Medicare Part D using beneficiary level claims data found a 
31% average annual increase in aggregate specialty drug spending from $8.7 billion in 
2010 to $32.8 billion in 2015.29 The top 50 selling brand-name specialty drugs in 2015 
had a weighted average retail price of $4,380, with a range of $250 to $43,000.29 The 
average net price for brand name specialty drugs grew at an average annual rate of 22% 
from $1,310 in 2010 to $3,590 in 2015 and a net per capita spending from $330 to $830 
in the same time frame.29   
Two studies looked at a sample of specialty drugs to determine the expected out-
of-pocket costs for individuals on Medicare Part D. One looked at 12 specialty drugs in 
201630 and the other looked at 30 drugs in 2019.60 In 2016, the expected out-of-pocket 




range was from $2,622 to $16,551 with an average of $8,109 across specialty drugs. Both 
studies found that a significant portion of spending occurred after the individual had met 
the catastrophic cap. In 2016, one-third of the total out-of-pocket spending occurred after 
the individual met the catastrophic cap and for 7 of the drugs, more than half occurred 
after the catastrophic threshold.30 In the 2019 study, the range of out-of-pocket spending 
above the catastrophic cap varied by drug from 13 to 86%. For 19 of the drugs, more than 
half of spending occurred after the cap.60 For the cancer drugs included in the study, 
enrollees paid at least 70% of total OOP after the cap.60  
Out-of-pocket costs can vary between PDPs from 2 to 14 times higher for brand 
drugs based on cost-sharing, tier placement, and the use of copays versus coinsurance.30 
Specialty drugs incur the highest costs when the drug is off formulary, 50% of the 12 
specialty drugs in the 2016 study were not included on all formularies.30 Two of the drugs 
included in the 2019 study were not included on any of the plans. For drugs that were not 
covered by some or all plans, the median annual cost when it was not included on the 
formulary ranged from $26,209 to $145,769. The median out-of-pocket costs for the 12 
specialty drugs that were on some but not all plans, found that the drug was at least 10 
times higher than the median cost if it was covered.60 
This is consistent with another study of specialty drugs for 6 uncommon cancers, 
which found that 99.21% of non-LIS individuals and 99.72% of LIS individuals in the 
sample reached the coverage gap and 94.4% non-LIS and 97.96% of LIS reached their 
catastrophic coverage.44 In this study the annual spending on specialty cancer drugs was 




spending was $4,870 overall and $2,689 while in the gap for non-LIS individuals and $44 
overall and $41 in the gap for LIS individuals.44  
Oral cancer drugs are a specific form of specialty drug that are associated with 
high drug costs. One study found that the median cost for a 30-day supply of these types 
of drugs was $10,060 with a range of $5,123 to $16,093 and median out-of-pocket costs 
for a median duration course ranged from $6,456 to $12,160.61 With these expenses, most 
beneficiaries on oral cancer drugs left the donut hole after 1.6 fills of the product.61 
Chronic myeloid leukemia (CML) is a rare cancer. A study that looked at CML patients 
who were taking targeted oral anticancer medication found that 81% of patients reached 
the catastrophic phase of coverage within the year and a majority of patients reached this 
point within the first month.62 The median costs for the first fill of the prescription was 
$3.7 for individuals with heavy subsidies, $6.9 for individuals with moderate subsidies, 
and $2,309.4 for individuals without subsidies.62 CML patients with subsidized Part D 
plans (68%) paid less than $2 for a 30-day supply, but 40% of individuals without 
subsidies paid out-of-pocket costs over $900.62 Another study looking at newly diagnosed 
CML patients found that individuals who did not have LIS coverage faced mean out-of-
pocket costs of $2,600 for the first 30-days of their treatment and were less likely to fill 
the initial prescription.63 For those that did fill the prescription, those with LIS subsidies 
initiated the prescription in 23.7 days on average and those without LIS subsidies took 
50.9 days.63  
To date, no studies have investigated the total Medicare Part D expenditures for 
all orphan drugs.  Previous studies related to Part D expenditures have focused on 




orphan indications. Studies on orphan drug expenditures in the United States have not 
provided aggregate or beneficiary level costs for Medicare Part D.  
Objectives 
Medicare Part D is a critical program for drug access for both individuals over the age 
of 65 and for individuals with qualifying disabilities. The primary purpose of this study is 
to determine how orphan drug expenditures in Medicare Part D compare to overall 
Medicare Part D drug expenditures. This research will fill the gap related to orphan drug 
costs and characteristics in this program. The specific questions this paper proposes are:  
1. How do orphan drug expenditures in Medicare Part D compare to overall 
Medicare Part D pharmaceutical expenditures?  
2. How do orphan drug expenditures for individuals over the age of 65 in Medicare 
Part D compare to orphan drug expenditures for individuals under the age of 65?  
3. How do orphan drug expenditures in Medicare Part D for: 
A. rare cancer drugs compare to orphan drug expenditures for drugs that do 
not treat a rare cancer?   
B. a drug with a single orphan indication compare to expenditures for drugs 
approved for multiple orphan indications?  
Data and Methods 
Conceptual model 
Levesque, Harris, and Russell’s patient centered healthcare access model provides 
a conceptual basis for this research.64 (Figure 4) The model utilizes individual and 
supply-side factors to inform the dimensions of accessibility of healthcare services. The 




systematic and individual components of access. The model is informed by a patient’s 
navigation of the healthcare system. Rare disease patients often face additional challenges 
while interacting with the healthcare system, but the model accounts for the key moments 
and forces that impact both the process and outcomes.   
Figure 4: Patient centered health care model 
Model by Levesque, Harris and Russell 
  
This paper is informed by the supply side factors that can result in the goal of 
access and positive health outcomes. Medicare Part D provides a mechanism for elderly 
and disabled individuals to access drugs in a cost-effective manner, which is reflected in 
the approachability and affordability domains of the model. Approachability describes 




factors such as eligibility, cost-sharing requirements, available subsidies, and drug 
coverage mechanisms, such as formularies, directly impact access and cost differences 
for individual patients. Health literacy can impact an individual’s ability to choose the 
best plan. However, the approachability of the system is influenced by the quality and 
availability of decision-making tools.   
Drug prices can impact both the acceptability and availability of drugs offered 
through Medicare Part D. Acceptability refers to the cultural and social forces that impact 
both the individual’s ability to engage in services and the way society judges the 
appropriateness of an individual seeking that type of care.64 The acceptability of using an 
orphan drug is impacted by the drug approval, drug marketing processes, and provider 
perceptions of new drugs. Availability through Part D is officially dependent on drug 
approval, but off-label use may present inequitable variations in access for different 
patients. The number of prescribers who are writing prescriptions for orphan drugs can 
help inform the availability and accommodation of an individual’s ability to find a 
medical professional who is knowledgeable in the condition and can provide a 
prescription for an appropriate treatment. The supply-side factors in this model can help 
frame the importance of the cost, prescriber, and beneficiary data as it relates to orphan 
drugs. It can also inform decisions about how to ensure adequate access to treatments.   
Data Source 
Drug cost data was accessed from CMS Medicare Part D Prescriber Public Use 
Files for the national prescription drug data from 2013-2017.65 The data is collected 
through CMS’s Chronic Conditions Data Warehouse and provides drug event records 




includes the number of claims, beneficiaries, prescribers, total drug costs, and specific 
information for beneficiaries over the age of 65. The aggregate costs paid by beneficiaries 
with and without low income subsidies was available for 2016 and 2017.  
Data on orphan drug characteristics were obtained from the IQVIA Institute for 
Human Data Science information was deidentified at the drug level.66 Data was from 
2016 national sales data and included total aggregate sales costs. A drug was considered 
an “orphan only” drug if it only had approved indicated orphan uses and a “partial 
orphan” drug if it had both orphan and common indications. The data also indicated if the 
drug had a single or multiple orphan indications. If the drug was a partial orphan, the 
order of approval was provided. These characteristics were verified through the FDA 
Orphan Drug Designations and Approvals database.67 Drug data included the costs and 
approval order for all orphan only and partial orphan drugs.  
Data preparation  
 Data is suppressed in the National drug files if the records are derived from 10 or 
fewer claims. To ensure that the missing data would not significantly impact results, 
totals from the national drug file spreadsheets were compared to the grand total aggregate 
costs. Missing data accounted for .002% or less for cost data in each year and .014% or 
less for cost data for age specific data. Any drug record with suppressed data was coded 
to indicate if the suppression was due to fewer than 10 claims for beneficiaries over age 
65 or under age 65. Proportional variables for the number of claims per prescribers, the 
number of claims per beneficiaries, the costs per claim, and the costs per beneficiary were 




and costs associated with individuals under the age of 65 compared to all claims, 
beneficiaries, and costs.  
 Any drug that received an orphan indication from 1983 to December 2016 was 
coded as “orphan only” or “partial orphan” if they had indications for rare and common 
uses. A variable was created to identify orphan drugs that had an indication for a rare 
cancer based on the listed indications in FDA’s database. Variables to identify if a drug 
had single or multiple orphan indications and the order of the approved partial indications 
(orphan first, common first, or concurrent) were also created.  
 A variable for approval order for partial indications was created in the sales data. 
For each partial orphan drug, the orphan spending was divided by total spending to 
calculate the total proportional orphan spending. Quintiles and quartiles were created 
based on total spending for the drugs.  The average proportional spending was calculated 
for all partial orphans by quartile, by quintiles, and by approval order group.  
 The list of orphan drugs was then compared to the Medicare Part D drug data and 
each drug was coded according to orphan only, partial orphan, or common only. None of 
the orphan only drugs had claims prior to the approved marketing date. Partial orphan 
drugs were only included as contributing to partial orphan spending after the earliest 
orphan marketing approval date. Any previous orphan associated spending would be 
considered “off-label” and beyond the scope of this study.    
Data analysis 
 Data analysis was conducted in Stata version 13.1. Descriptive statistics were 
calculated and recorded for all variables. This included frequency counts for categorical 




tested to see if they were normally distributed and all variables were found to be non-
parametric. Variables were then compared by drug type for each year. Kruskal Wallis 
tests were conducted to compare the statistical significance of the differences in values 
across continuous variables by orphan drug status. Means, standard deviation, and p-
values were reported. Unless otherwise noted, results were considered statistically 
significant at p=.05. 
 Sign tests were conducted to compare the differences between costs for 
individuals under and over the age of 65. Sign tests were also conducted to investigate the 
difference in costs paid by individuals with LIS and those with no subsidies. This was 
chosen over the Wilcoxon signed-rank test as the alternate hypotheses provide a direction 
for the differences between variables.68  
 In group analysis was completed for orphan drug specific variables. Kruskal 
Wallis tests were conducted to determine any differences in costs by approval order, rare 
cancer status, and for drugs with multiple orphan indications compared to drugs with 
single indications. Chi-squared tests were completed to investigate the statistical 
significance of suppression by age and drug type and age and rare cancer status.  
 The proportional share of orphan spending was not normally distributed. Kruskal 
Wallis tests were conducted on the weighted proportional differences for the quartiles, 
quintiles, and approval order groups. There was no statistical difference between groups 
for quartiles (p=.8786) or quintiles (p=.3762), the estimated costs for partial orphan 
spending were not calculated by these factors. There was a statistical difference (p=.020) 




 The mean proportional weight for all partial orphan drugs (0.23941) was applied 
to each partial orphan drugs’ total costs to create a new variable with the estimated 
orphan contribution to cost. The median proportional weight (0.08365) was also applied 
to costs for partial orphans. Proportional weighting by approval order group for orphan 
first (0.3808), common first (0.236), and concurrent approvals (0.2716) was also 
generated. Inverse variables for the estimated common costs for each of these three 
treatments were also calculated.  
 The three weighting applications were then used to calculate estimated means, 
ranges, and the aggregate sums of the estimated orphan and common spending by year. 
Pair-wise sign tests were conducted to compare the difference in estimated orphan 
spending by the three weighted estimate treatments. The partial estimates of orphan and 
common spending were added to the known common and orphan drug spending for each 
year and estimated totals by each model were reported.  
Results 
 There were a total of 17,022 drug records in Medicare Part D from 2013-2017. 
There were 305 unique orphan drugs with claims in this time frame. On average for all 
years, there were 25,283 prescribers, 423,566 claims, and 112,896 beneficiaries per drug 
per year. The differences in the average number of claims, beneficiaries, and prescribers 
by drug type were all statistically significant (p=.0001) for each year. (Table 9) 
Table 9: Beneficiary, cost, claim, and prescriber data by year 2013-2017 
Results are statistically significant at (p<.0001) by drug type for each year. 












































































































































































































 By drug type, total aggregate costs were $57.606 billion (8.67%) for orphan only 
drugs, $44.716 billion (6.74%) for partial orphan drugs, and $561.084 billion (84.58%) 
for common drugs. (Figure 5) The average total costs per year by drug type was 
statistically significant (p=.0001). In each year, partial orphan drugs had higher average 
costs than orphan only or common drugs. In 2017, orphan only drugs averaged $74.6 
million, partial orphan drugs averaged $134.8 million, and common drugs averaged $40.7 
million in mean costs.  





 There was a statistically significant difference in the costs per beneficiaries by 
drug type in each year (p=.0001). (Figure 6) Orphan only drugs had the highest average 
cost per beneficiary in each year. In the timeframe, the average cost per beneficiary for 
orphan drugs increased from $49,776 in 2013 to $92,753 in 2017. In the same timeframe, 
the average cost per beneficiary for common only drugs rose from $1,505 in 2013 to 
$3,920 in 2017.  
The lowest cost orphan only drug was $122 in 2017 for Cetylev, a drug to prevent 
or lessen hepatic injury. The drug with the maximum cost per beneficiary was $1,306,221 
for Strensiq a drug approved for hypophaosphatasia, a rare metabolic disease. It should 
also be noted that this drug is indicated for infantile and juvenile use and does not 
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and 40 beneficiaries in 2017 who submitted claims for Strensiq. Vimizim, another single 
orphan only indicated drug for mucopolysaccharidosis Type IV, a lysosomal storage 
disorder, is the only other drug to have per beneficiary costs over one million dollars. The 
common drug with the highest cost per beneficiary was $533,197 per beneficiary for 
Chenodal in 2017, which is indicated to dissolve gallstones. This drug had only 31 
beneficiaries listed and of to the total $16 million in expenditures, $13 million is 
associated with beneficiaries under the age of 65. The number of beneficiaries under the 
age of 65 is suppressed, but this does indicate very high costs for a small number of 
beneficiaries.  
Figure 6: Average costs per beneficiary by drug type from 2013 to 2017 
 
 Orphan only drugs had the highest average costs per claim across the timeframe 
and the difference by drug type was statistically significant and increased over time. 
(Figure 7) In 2017, the average cost per claim was $14,500.87 for orphan only drugs and 
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Figure 7: Average costs per claim by drug type from 2013 to 2017 
 
There was a statistically significant difference in the number of beneficiaries per 
prescriber across drug type by year. (Figure 8) For all years combined the average 
number of beneficiaries per prescribers was 1.31 for orphan only drugs, 1.72 for partial 
orphan drugs, and 1.69 for common drugs. There was a statistically significant difference 
in the number of claims per beneficiaries by drug type and year. (Figure 9) On average, 
there were 5.29 for orphan only, 4.91 for partial orphans, and 3.49 for common only drug 
claims per beneficiary.  
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Figure 9: Average claims per beneficiaries by drug type from 2013 to 2017 
 
 There was statistically significant difference in the aggregate total costs paid by 
individuals with LIS compared to individuals who do not have any subsidies (p<.0001). 
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paid according to orphan drug status in both 2016 and 2017. However, we are unable to 
determine the total number of claims for individuals with and without these subsidies.  
Table 10: Average aggregate total cost sharing by drug type with low-income 
subsidies and without subsidies 
    With low income subsidies (LIS) Without cost sharing subsidies 
    Mean (SD) Maximum p-value Mean (SD) Maximum p-value 
2016 by drug type   0.0001     0.0001 
  Orphan only 
60,981 
(233208) 2,391,922   
2,875,377 





(1185265) 9,839,207   
7,584,638 
(30820336) 263,742,128   
  Common 
304,062 
(1272528) 19,964,674   
4,373,747 
(17202718) 264,950,880   
2017 by drug type   0.0001     0.0004 
  Orphan only 
62,545 
(258323) 2,833,621   
3,076,643 





(514023) 3,643,136   
4,831,917 
(10108338) 56,076,244   
  Non orphan 
304,705 
(127259) 18,169,668   
4,491,525 
(18116438) 410,296,864   
 
 There were 449 orphan drugs in the national sales data set, 110 did not have any 
sales data for 2016. Of the remaining drugs, 255 were orphan only drugs with 100% 
orphan spending and 84 were partial orphan drugs. Of those, three drugs had only orphan 
spending and one drug had only common spending. The total aggregate spending in the 
national sales data had higher overall spending and a higher percentage of partial 
spending then was seen in the Part D data.  
 Of the weighted models, the mean proportional weighting resulted in the highest 
aggregate ($10.7 billion total) and mean costs ($28.7 million) and the median weighted 
model had the lowest aggregate ($3.7 billion total) and mean costs ($10.02 million). 




aggregate costs in the study period and $20.3 million in mean costs. These estimates were 
compared to the known costs for each year. (Figure 10)  
Table 11: Aggregate total and mean cost estimates for orphan associated spending 
using weighted models for partial orphan spending (in millions) 
Results are the estimated proportional orphan associated costs for partial orphan drug 
spending based on three models for weighting. Weighting by mean used a consistent 
factor of .23941. Weighting by median used a consistent factor of 0.08365. Weighting by 
approval order group was applied according to approval order with 0.3808 for orphan 
first, 0.236 for common first, and 0.2716 for concurrent approvals. 
   2013 2014 2015 2016 2017 Total 
Aggregate total partial orphan estimated costs (in millions) 
  By mean 1,528.841 1,817.829 2,223.444 2,554.148 2,581.263 10,705.525 
  By order 1,062.946 1,270.854 1,558.896 1,813.782 1,867.375 7,573.854 
  By median 534.146 635.113 776.826 892.368 901.841 3,740.293 
Mean estimated partial orphan costs (in millions)     
  By mean 21.533 25.603 30.047 33.171 32.266 28.701 
  By order 14.971 17.899 21.066 23.556 23.342 20.305 
  By median 7.523 8.945 10.498 11.589 11.273 10.028 
 
Figure 10: Aggregate total costs in billions of dollars by drug type and weighted 
estimates for partial orphan costs 





Age specific results 
 There was a statistically significant difference in the total costs, beneficiaries, 
claims, costs per beneficiary, and costs per claim for individuals over 65 and individuals 
under age 65 (p<.0001). We reject the null hypothesis that the two values are the same in 
favor of the alternate hypothesis that the value is larger for the over age 65 group in all 
cases except for costs per claim. For the costs per claim, we reject the null in favor of the 
alternate hypothesis that costs per claim are higher for individuals under 65 compared to 
costs per claim for individuals over. (Figure 11) 
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Overall, 31.11% of beneficiaries under 65. Claims per beneficiaries are highest 
for orphan only drugs and show more variation for orphan drugs by age. (Figure 11) 
Common only drugs showed less growth over time and are more similar between the age 
groups. Partial orphan drugs have the smallest proportional share of individuals under the 
age of 65 (20.32%). Individuals under 65 submitted 34.08% of all claims and 43.98% of 
orphan only claims. Individuals under 65 are responsible for 35% of all costs, 45.36% for 
orphan only costs, 38.77% for partial orphan drugs, and 34.29% for common only drugs.  
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 Costs per beneficiaries by age category steadily increased over time for orphan 
only drugs. Costs per beneficiaries for orphan only drug spending more than doubled in 
the time period ($59,548 in 2013 to $127,812 in 2017 while the costs per beneficiary for 
common only drugs increased from $3,109 to $4,908 in the same timeframe. (Figure 12) 
Orphan drug type was a statistically significant (p=.018) factor for the reason for 
suppression. (Table 12) 
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Table 12: Suppression by drug type and rare cancer status 
Data was suppressed if the number of claims or beneficiaries was less than 10. 
    65+ <65  
   N (%) N (%) p-value 
Drug Type     0.018 
  Orphan only 101 (42.62) 136 (57.38)   
  Partial orphan 25 (48.08) 27 (51.92)   
  Common 1495 (52.05) 1377 (47.95)   
  Total 1621 1540   
Orphan drug uses      <.0001 
  Rare cancer 61 (62.24) 37 (37.76)   
  Not rare cancer 65 (34.03) 126 (65.97)   
  Total 126 163   
 
Rare cancer 
 Rare cancer drugs for orphan only indications in Part D cost $24.01 billion 
between 2013 and 2017. This represents 3.61% of all spending in Part D and 41.68% of 
orphan only drug spending. There was not a statistically significant difference in the 
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(p=.095). (Figure 14) The average total costs of rare cancer orphan drugs were higher 
than their non-cancer counterparts ($97.9 million versus $70.4 million). The costs per 
beneficiary were seen to be statistically significant (p=.0014). With the rare cancer drugs 
costing $33,114.07 per beneficiary and non-cancer orphan drugs costing $68,151.63 per 
beneficiary. The maximum cost per beneficiary for a rare cancer drug was $146,130 per 
beneficiary compared to $1,306,221 for the highest cost non-cancer orphan drug per 
beneficiary.  
Figure 14: Average costs per beneficiary for rare cancer drugs 
 
The difference in the mean proportional costs for beneficiaries under the age of 65 
was found to be statistically significant (p=.0001). The mean costs attributable to 
beneficiaries under the age of 65 was 21.31% for all rare cancer drug spending and 
53.23% for non-cancer orphan drugs. (Table 13) A total of 98 rare-cancer drugs had 
suppressed records. Of those, 62% were suppressed due to data from individuals over the 
age of 65. For non-rare cancer drugs there were a total of 191 records with some 
suppression and individuals under the age of 65 represented 65.97% of the reason for 












2013 2014 2015 2016 2017




Table 13: Orphan drug in-group analysis for rare cancer, approval order, and 
multiple indications 
    
Average aggregate costs 
(in millions) Costs per beneficiary 
Costs 
<65 




value Mean (SD)  Max 
p-
value %  
Orphan drug uses   0.0952   0.0014  
  Rare cancer 
97.9 
(311.3) 3,310.5   
33,114.1 
(26,160.76) 146,130.1   21.31 
 Not rare cancer  
70.4 
(211.2) 2,551.1   
68,151.6 
(133,446.4) 1,306,221.0   53.23 
Approval Order     0.0001     0.0001  
  Orphan first 
78.3 
(111.5) 347.9  
60,226.9 
(32,477.2) 123,787.6  28.42 
  Common first 
119.1 
(303.7) 2,551.1  
25,082.3 
(35,137.4) 239,713.0  27.86 
  Concurrent  
146.0 
(240.8) 1,435.4  
17,201.8 
(22,735.6) 80,411.2  51.41 
  Orphan only 
62.6 
(220.8) 3,310.5  
70,528.0 
(130,562.6) 1,306,221.0  45.36 
  Common only  
35.7 
(168.7) 7,029.3  
2,686.8 
(12,007.1) 533,197.3  34.29 
Number of orphan 
indications   0.0001   0.513  
  Single orphan  
61.7 
(198.9)  2,551.1  
64,389.5 





(341.9) 3,310.5  
39,141.1 






Drugs with multiple orphan indications 
 There was a statistically significant difference in the average total costs for orphan 
drugs with one indication compared to drugs with multiple orphan indications (p<.0001). 
(Table 13) Across all years, there was not a statistically significant difference (p=.513) in 
the costs per beneficiary for orphan drugs with a single indication ($64,389.50) compared 
to drugs with multiple indications ($39,141.09). The proportional share of spending for 
individuals under the age of 65 was statistically significant (p=.0001) for orphan drugs 
with one indication (47.19%) compared to orphan drugs with multiple indications 
(33.67%). 
 There is a statistically significant difference in the average costs per beneficiary 
based on the approval order of the drugs. Across all years, the per beneficiary costs are 
highest for drugs with only an orphan drug approval ($70,528) or if the orphan approval 
occurred first ($60,226). The per beneficiary costs were lowest for drugs with only 
common indications ($2,686) and concurrent designations ($17,201). The highest cost 
per beneficiary was $1,306,221 in 2016 for an orphan only drug. The proportional share 
for individuals under the age of 65 was statistically significant (p=.0001) and highest for 
concurrent designations (51.41%) and orphan only (45.36%) drugs.  
Discussion 
Limitations 
The Medicare Part D data only includes spending through the Part D program and 
is not reflective of all orphan drug spending for Medicare beneficiaries. Any spending 




included. The purpose of this study is to determine the impact and characteristics of 
orphan drug spending through Medicare Part D, therefore, this limitation is not impactful.  
It is possible that suppressed records are more likely to be attributed to orphan 
drug spending due to the inherently small patient population for rare diseases. This could 
underestimate the impact of orphan drug spending in Part D. However, this impact should 
be very minimal as the missing data for any given year is negligible and for all years 
combined represents less than .18% of the total aggregate costs. 
The reason for drug use was not available in the data set and it is not possible to 
accurately identify orphan vs. non-orphan spending for partial orphan drugs or any off-
label drug use. As is consistent with other orphan drug studies,31 results are reported by 
drug type with partial orphan spending as a separate category of drug use to accurately 
report only what is known. Even if drug use cannot be determined, partial orphan drugs 
with approved orphan indications still benefit from government subsidies and have 
different cost patterns. Understanding market trends is still important for identifying 
trends and formulating policies.  
It is also possible that proportional spending for orphan and nonorphan use 
changes over time based on the rate of diffusion of awareness among patients and 
medical professionals for a new drug indication. Marketing dates were used to determine 
when official orphan drug use began, but drug data was only available based on the year. 
A partial orphan drug that received a marketing date after December 1st was considered a 
common drug until the following year to limit the over estimation of orphan associated 
costs. This was based on previous studies that found that there is a delay in the time it 




orphan spending would occur in the final weeks of the year directly after the marketing 
date, however, this may impact the true impact of orphan drug spending in the weighted 
analysis. This was not a consideration for orphan only spending as claims did not appear 
in the data set prior to the approval of any of the drugs.  
Estimations on the anticipated impact of partial orphan drugs was conducted 
through proportional weighting based on estimates from national sales data. The 
weighting may be different for the general marketplace compared to the Medicare 
population. Weighting could only be calculated on group characteristics and not by a 
specific drug. Additionally, weighting was only available for 2016 sales data and was 
applied consistently across all years. This could inaccurately represent the true weighting 
of orphan drug proportional spending in Medicare Part D in the timeframe of this study. 
Estimations on the orphan versus common spending associated with partial orphan drugs 
should be viewed as estimations and a starting point for future inquiry.  
This paper is unable to address any claims that were denied or differences in 
approval patterns for orphan and non-orphan drugs. If an individual is on multiple 
medications or drugs, we cannot look at overall beneficiary spending patterns. We are 
also unable to determine differences according to tiers, formulary restrictions, or MA-PD 
versus PDP plans. We also do not have any context for additional reimbursement 
programs or financial assistance support for the cost sharing burden on patients. Any 
available information about cost sharing is at the aggregate drug level and we cannot 
calculate per beneficiary cost sharing. This analysis is critical for future studies on the 




of scope for this analysis. This study is the first to investigate the cost and claim trends 
for all orphan only or partial orphan spending in Medicare Part D.  
Orphan drug spending 
Supply-side factors of approachability, acceptability, availability and 
accommodation, affordability, and appropriateness are all critical in patients achieving 
appropriate access to needed healthcare services which result in positive health outcomes. 
This project focused on the affordability aspects of access, while also providing some 
evidence for the availability and accommodation of access to orphan drugs based on the 
number of prescribers per beneficiary.  
In previous studies orphan drug spending accounted for between 7.9-9.5% of total 
pharmaceutical spending.13,33,69 We can confidently attribute 8.6% to pure orphan only 
spending and an additional 6.74% to partial orphan spending. Using the estimates from 
the weighted models total orphan percentage is 10.3% using the mean model, 9.83% 
using approval order model, and 9.25% using the median model.  
Despite the small proportion of total Part D spending, there was a clear difference 
in the average costs, costs per beneficiary, and costs per claim for orphan only drugs, 
partial orphan drugs, and common drugs. A previous study of orphan drug prices found 
that 80.4% of orphan drugs had an average cost per patient of over $6,000, this study 
found much higher per beneficiary costs.13 In 2017, the average per beneficiary cost was 
$92,753 for orphan only drugs and $31,638 for partial orphan drugs.  
A CBO report found that brand name specialty drug spending in 2015 was 
$33,460 per beneficiary.29 In this study, 2015 per beneficiary partial orphan drug 




year was much higher at $64,618 per beneficiary. Orphan drugs are often considered a 
subset of specialty pharmaceuticals, but these differences provide a compelling need to 
further investigate our payment mechanisms for covering orphan only drugs and consider 
programs that specifically target the unique characteristics of rare disease patients. 
The percentage of partial orphan drugs in this study was 28% which is slightly 
higher than in previous studies which found between 18 and 22% of orphan drugs were 
partial orphans.13,31 This difference is likely due to the fact that the general market is 
more likely to include claims for pediatric or juvenile orphan drugs compared to the 
Medicare population whose target population is mainly individuals over the age of 65. 
Orphan only drugs in the study have a higher percentage of claims attributable to 
individuals under the age of 65 compared to common or combined drugs.  
Aggregate average costs per drug were highest for partial orphans compared to 
orphan only or common drugs. For all years combined, the average cost of an orphan 
only drug was $62.6 million, for a common drug was $35.7 million, and for a partial 
orphan drug $119.8 million. These trends do not persist for per beneficiary or per claim 
costs, but should be acknowledged and understood when considering policy reforms for 
stimulating orphan drug development.  
The number of beneficiaries per prescribers was statistically significant across 
years and was lower in each year for orphan only drugs. It is often difficult for 
individuals with rare diseases to find knowledgeable medical providers. This difference 
could point towards the overall consolidation of rare disease experts. Future research 
should investigate additional characteristics of providers to determine where individuals 




We only have information about the individual cost share at a total aggregate drug 
level and not per beneficiary. Cost sharing was significantly higher for individuals 
without cost-sharing subsidies. The orphan only drug that had the highest total cost-
sharing amount in 2017 was Revlimid, a treatment for multiple myeloma.30 Individuals 
who did not have cost sharing subsidies and received Revilimid were responsible for a 
total $143.9 million. The drug had a total of 37,399 beneficiaries in 2017. By 
comparison, individuals without cost sharing subsidies on the common drug Eliquis, an 
anticoagulant, were responsible for a total of $410.3 million. A total of 1,064,170 
beneficiaries who used the drug. In general, 30% of people with Part D have LIS.30 If we 
were to use the assumption that 70% of beneficiaries did not receive any subsidies this 
would mean a per beneficiary cost of $550.79 for Eliquis and $5,496.88 for Revlimid. It 
is unlikely that either of these drugs would be the only prescription a beneficiary would 
need in a single year.  
Age specific results 
In Medicare, 14.4% of beneficiaries are under the age of 65,65 but in this study 
34.08% of all claims and 31.11% of beneficiaries  were individuals under the age of 65. 
Individuals in Medicare under the age of 65 are more likely to have multiple chronic 
conditions compared to their older counterparts, which could account for this higher 
percentage of overall claims.41,46 It is possible that the total number of beneficiaries is 
closer to 14%, but we cannot determine if an individual beneficiary is responsible for 
multiple drug claims across the data set.   
Higher per beneficiary and per claim costs for beneficiaries under the age of 65 




more pronounced for orphan drugs and partial orphan drugs then common drugs. This 
could be based on the concerted effort to include rare diseases on the list of 
compassionate allowances.40 It is also possible that individuals with a rare disease 
diagnosis have access to resources that help them to apply for Social Security benefits, 
which makes them eligible for Part D. The large share of orphan drug spending 
attributable to individuals under the age of 65 indicates the overall need for public 
programs to help rare disease patients access treatments. Future research should explore 
the additional demographic and diagnosis characteristics of Medicare enrollees on 
Medicare. Geographic variation based on the accessibility of rare disease providers and 
programs to connect individuals with additional assistance may provide additional 
information about equity issues or barriers to enrollment.   
Rare Cancer 
A total of $24.01 billion is attributed to orphan only rare cancer drugs and an 
additional $16.34 billion is attributed to rare cancer drugs with combined orphan and 
non-orphan indications. The average aggregate total cost of rare oncology drugs ($97.9 
million) was higher than non-cancer orphan drugs ($70.4 million), but the costs per 
beneficiary were significantly higher for non-cancer drugs ($68,152) compared to rare 
cancer orphan drugs ($33,114). The total sum of all rare cancer spending for all years was 
$40.347 billion or 39.43% of all orphan drug spending from 2013 to 2017. This is 
consistent with the 2013 finding that oncology drugs represented 40.7% of orphan drug 
spending in a study of sales data.31  
Individuals over the age of 65 account for 78.69% of the expenditures for rare 




oncology products. It is possible that beneficiaries are receiving medications for both 
cancer and non-cancer orphan drugs, we cannot make determinations about the diagnostic 
characteristics of rare disease patients on Part D.  
Drugs with multiple orphan indications 
 Per beneficiary costs for orphan drugs with multiple indications are not 
statistically significant compared to per beneficiary costs for orphan drugs with one 
indication. Previous studies have found that drugs with multiple orphan indications have 
higher prices,15 however, the disease prevalence of the first indication is an additional 
contributing factor which was not investigated in this study.70 The range in values for 
costs per beneficiaries for orphan drugs with a single orphan indication ranges from 
$90.42 per beneficiary to $1,306,221 per beneficiary. Orphan drugs with multiple 
indications range from $142.96 to $437,481.20 per beneficiary. This range provides 
evidence for the large range of costs in orphan drug spending. By contrast, the minimum 
per beneficiary cost for common drugs is $.01 per beneficiary. Drugs that entered the 
market as an orphan drug first or that are only indicated as orphan drugs are associated 
with higher costs per beneficiaries.  
Policy implications and future research  
Although the overall proportion of orphan drug spending is low, the per 
beneficiary costs and the cost share individuals may be responsible for are quite high if 
coinsurance is utilized. This is consistent with other findings related to orphan and 
specialty drugs in the U.S.13,29,31 Policies need to be implemented to curb the burden of 
high costs of drugs in the United States. There have been a number of strategies proposed 




transparency, and utilizing negotiation techniques.71 One of the most compelling policy 
changes would be to allow CMS to negotiate drug prices directly with pharmaceutical 
companies, a strategy that has been successful for our international counterparts.71–73 
Legislative efforts to implement these types of policies are consistently blocked by 
lobbying efforts by pharmaceutical companies.  
As policies are formulated to control drug costs, it is essential to curb spending 
while not stifling innovation. Although pricing is an issue for orphan drugs, there is a 
large unmet need for patients with over 6,000 rare diseases not having any approved 
therapy. Understanding the patient impact and ethical implications of access to orphan 
therapies is crucial when formulating new policies or revisiting the incentives outlined in 
the ODA.74,75 Increasing the transparency of the orphan drug development process will be 
critical to formulating strategies that can more successfully balance competing cost and 
access needs.14,18  
This paper provides additional evidence for the use of Medicare by individuals 
under the age of 65 who have high drug costs. Without access to Medicare, individuals 
may not be able to access these drugs. Future research should investigate the ease of 
gaining access to orphan drugs under Medicare to understand if there are claim denials 
for orphan drugs. Although orphan drug spending only represented 7% of expenditures in 
Medicare Part D, that is unlikely to represent the need. Additional research should be 
conducted to determine how easy it was to gain access to Medicare for rare disease 
beneficiaries.  
Some beneficiaries who require orphan drugs may also be dual beneficiaries with 




programs to provide reduced cost drugs or waive copays. Understanding how these 
programs contribute to overall costs and medication adherence decisions would provide a 
more complete picture for the orphan drug cost ecosystem. In the future, health insurance 
plans designed for individuals with high drug costs may be necessary to curb unnecessary 
spending, while providing needed access. 
Future research should be conducted to explore beneficiary level data both to 
capture total costs per rare disease patient and the cost-sharing mechanisms. There are 
clear cost differences for drugs on and off formularies,30 it is critical for patients with 
high cost drugs to have an easy way to identify the correct plan. It may not be possible 
for rare disease patients on multiple medications to choose a plan that would provide an 
affordable way to access all needed drugs. Research should also be conducted to 
determine how patients navigate plan enrollment.   
The costs per beneficiary have the potential to be very large, even after 
catastrophic caps are met.30,46,60 Growing concerns related to the high out of pocket costs 
for U.S. patients may require that we restructure our medical assistance programs. The 
potential costs an individual may be responsible for may be prohibitive for most 
individuals contributing to overall financial toxicity or worse health outcomes. 
Demographic and geographic variability should be explored to determine if inequities are 
developing due to programmatic structures.  
As conversations related to health care reform and controlling costs continue, 
understanding spending for the rare disease population will help ensure better health and 
financial outcomes. Internationally, rare disease country specific plans allow a holistic 




disease needs in new national policy could provide a better roadmap for cost-effective 
patient centric initiatives. Some states have begun to form Rare Disease Advisory 
Councils and although many policy initiatives are critical to address at the state level, 
there should be an investment in both state and country level planning. Healthcare policy 
initiatives should include the patient voice and the high-costs of orphan drugs should 
ensure that rare disease patient advocates have a seat at the table.  
Conclusion 
Although orphan drug spending comprises a relatively small share of overall 
Medicare Part D expenditures, the per beneficiary and per claim costs can be very high. 
Almost half of the costs associated with orphan drugs are attributed to beneficiaries under 
the age of 65. Rare cancer drugs that are only indicated for rare use represent 3.6% of all 
spending in Medicare Part D. Drug costs will continue to be a significant portion of our 
medical costs. More strategies must be undertaken to address the high costs and ensure 
appropriate access to patients who need high cost drugs. Previous studies on Part D 
trends have focused on specialty drugs or a subset of orphan drug spending. The high cost 
and growth of orphan drugs provides a compelling reason to conduct this analysis and 
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There are an estimated 30 million patients in the United States living with one or 
more rare diseases.1 There is limited research on most rare diseases which perpetuates 
challenges for patients, researchers, and medical professionals.4,6,7 High-quality data and 
an understanding of the patient experience are critical to establishing effective healthcare 
infrastructure that maximizes positive patient health outcomes and minimizes costs. This 
dissertation research is comprised of three papers related to key aspects of the rare 
disease experience in the United States.   
For most rare diseases, basic information such as the natural history of the disease 
and epidemiological data is limited or missing.4,10 The importance of including the 
patient voice has become an established theme in the rare disease community and 
literature.32–35 However, it is important to note the differences in data availability for 
diseases with and without an orphan drug. Diseases with orphan drugs are more likely to 
have patient organization representation, which are often critical for driving research.33–35 
Other infrastructure such as the ability to code and track the disease in electronic health 
systems is also more likely if a disease has a drug, which may make it is easier to 
establish treatment protocols or justify medical needs to an insurance company.  
Patients interfacing with insurance companies often feel that the insurance 
company does not understand the medical necessity of certain medical procedures or 
products. Caregivers describe the necessity of becoming an expert on the disease or 
relying on medical professionals in the care team to navigate the entire insurance 




that can help them cover medical expenses. Finding the appropriate mix of insurance and 
social service supplemental support can be complex and there are few mechanisms to 
help patients plan their long-term health care needs.  
Medicare Part D provides drug coverage for individuals over the age of 65 or with 
a qualifying disability. Roughly 85% of Medicare Part D beneficiaries are over the age of 
65, but costs per claim are higher for individuals under the age of 65. The total 
expenditures for orphan drugs in Medicare Part D are around 10% of all expenditures, but 
the high costs for individuals under the age of 65 indicates the need to consider this group 
when preparing for future healthcare expenditures and instituting any healthcare reforms.  
Our healthcare infrastructure is currently not equipped to capture detailed 
information about rare diseases or track diseases across information sources. Within 
insurance, patients have a complicated journey to navigate what will be covered and the 
onus falls on patients or caregivers to track the details of healthcare interactions and 
navigate program eligibility. Insurance and medical assistance programs allow patients to 
access needed services or benefits, but geographic inequities have been described. 
Additional research will be necessary to determine how many rare disease patients have 
been denied enrollment in Medicare or Medicaid benefits and the associated wait times to 
receive a determination of eligibility.   
Policy implications  
All healthcare policy initiatives should be patient-centric and consider patient 
privacy protections. This research did not address demographic equity issues, but based 
on the persistent inequities in the U.S. healthcare system, future research should identify 




regions may have better access to medical knowledge through increased access to elite 
providers or institutions. Additionally, differences in access based on state-based 
eligibility differences, especially related to Medicaid expansion, can also lead to 
geographic disparities.  
Expanding medical technologies and investing in an increased medical 
understanding of rare diseases, must also be met with ensuring that all patients can 
benefit to avoid further reinforcing health disparities in this country. One way to ensure 
that this is accomplished is to leverage telemedicine to access providers outside of 
geographic areas. Another solution is to ensure that insurance plans allow for patients to 
see disease specialists outside of their network without incurring additional costs, 
especially in cases where only a handful of medical experts may exist. It is also important 
that diseases without current pharmaceutical investment still have representation in policy 
initiatives and opportunities to establish natural history studies to generate basic research.  
It is critical to continue to invest in research for rare diseases and find ways to 
continue to educate clinicians, insurance companies, and policymakers. Health 
information websites and institutions should commit to higher data quality, including 
providing more attribution to the previous research that has been conducted so the source 
and relevance of the data can be assessed. The U.S. should also continue to participate 
and implement efforts related to standardized nomenclature of rare diseases, such as the 
work being conducted by the Monarch Initiative and IRDiRC.25,27 The U.S. should also 
commit to adopting the infrastructure that can help increase the visibility of rare diseases, 




Orphan drugs represent a large part of the focus for rare diseases, but are only 
available for about 300 of the identified 6,500 rare diseases.37 Orphan drug prices are 
very high in the United States and represent higher per capita spending in programs for 
Medicare Part D compared to drugs for common conditions. However, these treatments 
are often life altering for patients, as is the case for individuals with spinal muscular 
atrophy. Payers are not always equipped to evaluate the benefit of these drugs and 
patients and caregivers are often tasked with building a case for their coverage when a 
new drug enters the market, which can delay access. Future policies should address 
strategies to help prepare insurance companies for newly approved drugs. 
The increasing use of genetic information in the drug development process has the 
potential to change how we treat rare diseases.38–41 However, our current infrastructure 
may not be equipped to track genetic differences for patients and inequities may dictate 
who can access these advanced therapies. Especially for treatments that have a high cost. 
Changes in pharmaceutical pricing could address some of these concerns, including 
allowing CMS to directly negotiate drug prices with pharmaceutical companies. As a 
country, we will need to find policies that can balance how we incentivize research and 
development, our desire for medical innovation, patient access, and overall costs.  
To realize any of our policy goals it we must continue to participate 
internationally and include key stakeholders in policy initiatives. Rare diseases are a truly 
global public health challenge and should be addressed as such, while ensuring unique 
features of the U.S. healthcare system and our demographics are accounted for in 
implementation. We should recognize the unique role clinicians play as the front line of 




and receiving knowledge about rare diseases and as a partner in connecting patients to 
appropriate resources. Clinicians are critical in helping capture data related to patient 
prevalence and providing details related to the medical necessity of certain treatments, 
therapies, and medical equipment. Payers, including private insurance companies, 
Medicare, and Medicaid, need to understand the importance of patient access to care that 
is deemed medically necessary. Finding better ways to evaluate these recommendations 
in a timely manner, especially for diseases with a small patient population can help 
patients financially prepare for needed medical expenses and cut down on more serious 
and costly medical complications.  
Patients make up the final group of stakeholders that must hold a seat at the table 
for any policy reform efforts. It is important to recognize the different experience that 
patients may face if their disease does not have an established patient organization or if 
the disease has not been widely studied. It is important to facilitate programs that will 
help connect patients to information and to access healthcare, especially if experts fall 
outside of their geographic area or insurance network. It would also be beneficial to 
identify ways to drive collective action without splintering resources or generating too 
many independent data sources that cannot be integrated and shared through data sharing 
agreements. The rise of patient advisory councils or rare disease committees at the state 
level and for drug development have been a driving force in progress to date.7,33,35 
However, a rare disease national plan should be developed for the United States to keep 
pace with our European and international colleagues and to chart priority areas of growth 







1. National Organization for Rare Disorders (NORD). NORD (National Organization for 
Rare Disorders). https://rarediseases.org/. Accessed April 19, 2017. 
2. Groft SC, de la Paz MP. Rare diseases - avoiding misperceptions and establishing 
realities: the need for reliable epidemiological data. Adv Exp Med Biol. 2010;686:3-14. 
doi:10.1007/978-90-481-9485-8_1 
3. Kole A, Faurisson F. Rare diseases social epidemiology: analysis of inequalities. Adv 
Exp Med Biol. 2010;686:223-250. doi:10.1007/978-90-481-9485-8_14 
4. Pelentsov LJ, Fielder AL, Laws TA, Esterman AJ. The supportive care needs of 
parents with a child with a rare disease: results of an online survey. BMC Fam Pract. 
2016;17:88. doi:10.1186/s12875-016-0488-x 
5. R de Vrueh, ERF Baekelandt, JMH de Haan. Priority medicines for Europe and the 
world “A public health approach to innovation.” World Health Organizatoin; 2013. 
https://www.who.int/medicines/areas/priority_medicines/BP6_19Rare.pdf. Accessed July 
2, 2019. 
6. Basch E, Bennett AV. Patient-reported outcomes in clinical trials of rare diseases. J 
Gen Intern Med. 2014;29 Suppl 3:S801-803. doi:10.1007/s11606-014-2892-z 
7. Bronstein MG, Kakkis ED. Patients as key partners in rare disease drug development. 
Nat Rev Drug Discov. 2016;15(11):731-732. doi:10.1038/nrd.2016.133 
8. Koay PP, Sharp RR. The role of patient advocacy organizations in shaping genomic 
science. Annu Rev Genomics Hum Genet. 2013;14:579-595. doi:10.1146/annurev-genom-
091212-153525 
9. Hall JG. The role of patient advocacy/parent support groups. South Afr Med J Suid-Afr 
Tydskr Vir Geneeskd. 2013;103(12 Suppl 1):1020-1022. 
10. Pelentsov LJ, Fielder AL, Laws TA, Esterman AJ. Development of the parental needs 
scale for rare diseases: a tool for measuring the supportive care needs of parents caring 
for a child with a rare disease. J Multidiscip Healthc. 2016;9:425-433. 
doi:10.2147/JMDH.S113898 
11. About Monarch. https://monarchinitiative.org/page/about. Accessed July 15, 2019. 
12. International Rare Diseases Research Consortium. International Consortium of 
Human Phenotype Terminologies (ICHPT). IRDiRC. 
http://www.irdirc.org/activities/task-forces/international-consortium-of-human-




13. Genetic and Rare Diseases Information Center (GARD), National Center for 
Advancing Translational Sciences. List of FDA Orphan Drugs. 
https://rarediseases.info.nih.gov/diseases/fda-orphan-drugs. Accessed July 19, 2018. 
14. Dolled-Filhart MP, Lordemann A, Dahl W, Haraksingh RR, Ou-Yang C-W, Lin JC-
H. Personalizing rare disease research: how genomics is revolutionizing the diagnosis and 
treatment of rare disease. Pers Med. 2012;9(8):805-819. doi:10.2217/pme.12.97 
15. Schee Genannt Halfmann S, Mählmann L, Leyens L, Reumann M, Brand A. 
Personalized medicine: What’s in it for rare diseases? Adv Exp Med Biol. 2017;1031:387-
404. doi:10.1007/978-3-319-67144-4_22 
16. Owusu Obeng A, Fei K, Levy KD, et al. Physician-reported benefits and barriers to 
clinical implementation of genomic medicine: a multi-site IGNITE-network survey. J 
Pers Med. 2018;8(3). doi:10.3390/jpm8030024 
17. Tambuyzer E. Towards a framework for personalized healthcare: lessons learned 









LOGISTIC REGRESSION OUTPUT FOR DISEASE NAMING CONVENTIONS  
 
Statistically significant coefficients are indicated using the following symbols: *=p<.05, 
**=p<.01, ***=p<.001 
Table A: Broad name     
  Coefficient SE 
Orphan drugs 1.185 0.717 
Rare cancers 0.767 0.73 
Orphan drug* Rare cancer -1.186 0.977 
Constant -1.386* 0.559 
   
Table B: Specific name     
  Coefficient SE 
Orphan drugs 1.846 1.149 
Rare cancers 0.000 1.451 
Orphan drug* Rare cancer 0.252 1.616 







LOGISTIC REGRESSION OUTPUT FOR DATA WEBSITES WITH 
PREVALENCE ESTIMATES 
 
Statistically significant coefficients are indicated using the following symbols: *=p<.05, 
**=p<.01, ***=p<.001 
Table A: Prevalence estimate listed in GARD 
  Coefficient SE 
Orphan drugs 0.747 1.268 
Rare cancers -1.210 1.202 
Orphan drug* Rare cancer -1.210 1.599 
Constant -2.944 1.026 
   
Table B: Prevalence estimate listed in NORD 
  Coefficient SE 
Orphan drugs 2.944** 1.119 
Rare cancers 1.846 1.149 
Orphan drug* Rare cancer -3.232* 1.353 
Constant -2.944** 1.026 
   
Table C: Prevalence estimate listed in Orphanet 
  Coefficient SE 
Orphan drugs 0.811 0.645 
Rare cancers 0.405 0.639 
Orphan drug* Rare cancer -1.212 0.908 
Constant -0.405 0.456 
   
Table D: Prevalence estimate listed in Genetics home 
reference 
  Coefficient SE 
Orphan drugs 2.197* 0.869 
Rare cancers 1.099 0.907 
Orphan drug* Rare cancer -3.296** 1.256 
Constant -2.197** 0.745 
   
Table E: Prevalence estimate listed in Genereviews 
  Coefficient SE 
Orphan drugs 1.558 1.168 
Rare cancers 1.558 1.168 
Orphan drug* Rare cancer 0.000 Omitted 
Constant -2.944** 1.026 




Table F: Prevalence estimate listed in Medscape 
  Coefficient SE 
Orphan drugs 2.744* 1.12 
Rare cancers 1.558 1.168 
Orphan drug* Rare cancer -0.952 1.332 
Constant -2.944 1.026 
   
Table G: Prevalence estimate listed in OMIM 
  Coefficient SE 
Orphan drugs 17.785 Omitted 
Rare cancers 15.993 0.874 
Orphan drug* Rare cancer -17.322 0.974 
Constant -18.190 0.456 






LINEAR REGRESSION OUTPUT FOR PREVALENCE ESTIMATES WITH 
DATA QUALITY FACTORS BY DISEASE 
 
Statistically significant coefficients are indicated using the following symbols: *=p<.05, 
**=p<.01, ***=p<.001 
Table A: Number of estimates   
  Coefficient SE 
Orphan drugs 7.450 2.212 
Rare cancers 2.500 2.212 
Orphan drug* Rare cancer -0.950 3.128 
Constant 0.800 1.564 
   
Table B: Number of quality estimates   
  Coefficient SE 
Orphan drugs 1.400* 0.539 
Rare cancers 0.800 0.539 
Orphan drug* Rare cancer 0.100 0.763 







LOGISTIC REGRESSION OUTPUT FOR PREVALENCE ESTIMATES WITH 
DATA QUALITY FACTORS BY ESTIMATE  
 
Statistically significant coefficients are indicated using the following symbols: *=p<.05, 
**=p<.01, ***=p<.001 
Table A: Author     
  Coefficient SE 
Orphan drugs <.0001 0.15 
Rare cancers -0.227 0.141 
Orphan drug* Rare cancer 0.100 0.16 
Constant 0.500*** 0.135 
   
Table B: Date     
  Coefficient SE 
Orphan drugs -0.006 0.136 
Rare cancers -0.324* 0.127 
Orphan drug* Rare cancer 0.076 0.145 
Constant 0.688*** 0.122 
   
Table C: Attribution     
  Coefficient SE 
Orphan drugs 0.180 0.202 
Rare cancers 0.019 0.19 
Orphan drug* Rare cancer -0.149 0.216 
Constant 0.563** 0.181 
   
Table D: All quality factors 
  Coefficient SE 
Orphan drugs 0.053 0.119 
Rare cancers -0.056 0.112 
Orphan drug* Rare cancer 0.008 0.127 







LOGISTIC REGRESSION OUTPUT FOR PREVALENCE INFRASTRUCTURE 
VARIABLES 
 
Statistically significant coefficients are indicated using the following symbols: *=p<.05, 
**=p<.01, ***=p<.001 
Organization     
  Coefficient SE 
Orphan drugs 3.121*** 0.839 
Rare cancers 1.792* 0.722 
Orphan drug* Rare cancer -1.792 1.142 
Constant -1.386* 0.559 
    
Disease specific organization   
  Coefficient SE 
Orphan drugs 2.197* 0.869 
Rare cancers 1.099 0.907 
Orphan drug* Rare cancer -1.946 1.123 
Constant -2.197* 0.745 
    
Registry     
  Coefficient SE 
Orphan drugs 3.145** 1.12 
Rare cancers 1.210 1.202 
Orphan drug* Rare cancer -2.797* 1.4 
Constant -2.944** 1.026 
    
Medical center     
  Coefficient SE 
Orphan drugs 2.140** 0.775 
Rare cancers 1.253 0.668 
Orphan drug* Rare cancer -1.253 1.109 
Constant -0.405 0.456 
    
ICD-10 specific     
  Coefficient SE 
Orphan drugs 2.539* 1.123 
Rare cancers 1.210 1.202 
Orphan drug* Rare cancer -1.423 1.369 
Constant -2.944 1.026 
    




  Coefficient SE 
Orphan drugs 2.582*** 0.794 
Rare cancers 0.636 0.812 
Orphan drug* Rare cancer -0.636 1.065 







LINEAR REGRESSION OUTPUT FOR PREVALENCE INFRASTRUCTURE 
VARIABLES  
 
Statistically significant coefficients are indicated using the following symbols: *=p<.05, 
**=p<.01, ***=p<.001 
Table A: Number of organizations 
  Coefficient SE 
Orphan drugs 4.200*** 1.107 
Rare cancers 1.850 1.107 
Orphan drug* Rare cancer -0.800 1.566 
Constant 0.250 0.783 
   
Table B: Number of medical centers   
  Coefficient SE 
Orphan drugs 15.350* 5.928 
Rare cancers 7.150 5.928 
Orphan drug* Rare cancer 6.950 8.384 
Constant 1.500 4.192 
   
Table C: Number of clinical trials   
  Coefficient SE 
Orphan drugs 25.55 84.229 
Rare cancers 41 84.229 
Orphan drug* Rare cancer 273.9* 119.117 
Constant 0.9 59.559 
   
Table D: Number of active clinical trials   
  Coefficient SE 
Orphan drugs 8.200 24.496 
Rare cancers 11.150 24.496 
Orphan drug* Rare cancer 83.250* 34.643 
Constant 0.250 17.321 
   
Table E: PubMed results     
  Coefficient SE 
Orphan drugs 2054.150 1702.497 
Rare cancers 621.100 1702.497 
Orphan drug* Rare cancer 4733.800 2407.694 
Constant 425.100 1203.847 
   




  Coefficient SE 
Orphan drugs 100.450 122.27 
Rare cancers 85.050 122.27 
Orphan drug* Rare cancer 399.450* 172.916 







QUALITATIVE INTERVIEW SCRIPT  
 
Interview Questions 
Hi, thank you for taking the time to speak with me today. I am interested in speaking 
today about your health insurance experience.  
Obtaining insurance  
1. Have you ever experienced difficulty getting insurance or experienced an 
extended period, more than three months, of not having insurance? Could you tell 
me about that experience?  
2. Are you satisfied with your current health insurance?  
a. Can you tell me anything about what type of insurance you have (public, 
private, from an employer, etc.)?  
Coverage/ Orphan drugs 
3. Can you tell me about a time that you might have experienced any difficulties 
obtaining medical care based on your insurance? (This might include things such 
as seeing your preferred doctor or having treatments or medications covered) 
4. Did you ever experience a significant change in your insurance? 
a. What was your role in bringing that about?  
b. Was there anyone who helped you navigate or bring about that change?  
Cost-sharing 
Many insurance plans use a variety of methods to share the cost between insurance and 
the patient. I am now going to ask you about a few of these different methods. Don’t 
worry if you are unfamiliar with any of these terms or concepts, just tell me about 
anything you do know or believe you have experienced.  
5. A premium is the amount of money patients must pay for their insurance, usually 
on a monthly basis. Do you know if you have a premium and how much you pay?  
6. A copay is a fee that some people have to pay before certain types of 
appointments or doctor’s appointments. Usually, you would pay this when you 
arrive at the doctor. Do you know if you are required to pay a copay? 
7. Sometimes insurance uses coinsurance, where insurance will cover some portion 
of the medical expense and the patient must cover the rest. Often you would 
receive this as a bill after you have attended your appointment. Do you know if 
your insurance company requires coinsurance  
8. A deductible is sometimes set by insurance companies and is the amount a patient 
needs to spend before the insurance company will cover any additional costs. Do 




9. Is there anything else about your experience with fees and payments you 
experienced? 
Health literacy  
10. In general, how comfortable are you navigating your insurance? 
a. Do you think your comfort level has changed over time?  
Navigating the system 
11. Has anyone helped you understand or navigate the system, this might include 
things like organizations, friends, or peer-support networks?  
Additional Assistance 
12. Can you tell me if there any other programs or services that you are able to use 
that provide any financial or medical support?  
a. How easy was it to access this source of support?  
b. How did you learn about these resources?  
Final Questions 
13. If you could make a wish list to make your experience better, what would that 
include?  






QUALITATIVE CODEBOOK  
 
 Code Description 
1.    Assistance Financial or in-kind assistance received to cover the cost of medical 
treatments, equipment, services, or procedures. This also includes 
information related to how easy it was to access this type of support.  
1.1 Early 
intervention  
Service and supports that are available to children younger than three 
years old with developmental delays and disabilities. Programs exist in 
every state and covered services are based on needs but often include 
speech and physical therapy. 
1.2 Grants Financial assistance for medical equipment, treatments, services, or 
procedures that are received from funds that the participant applied to 
from the government, organizations, or foundations. 
1.3 None When the participant stated that they do not access any additional 
financial assistance or support programs.   
1.4 Organization 
or companies 
Financial or in-kind assistance for medical equipment, treatments, 
services, or procedures that is provided by a private or non-profit 
organization.  
1.5 Peers or 
family 
Financial or in-kind assistance for medical equipment, treatments, 
services, or procedures that is provided by peers, friends, or family 
members.  
1.6 Pharma Financial or in-kind assistance from pharmaceutical companies. 
Usually related to accessing low cost treatments or to cover the co-
pays and associated fees for the treatment.  
1.7 School Financial or in-kind assistance for medical equipment, treatments, 
services, or procedures that is provided by schools or the school 
district.  
1.8 State Financial or in-kind assistance for medical equipment, treatments, 
services, or procedures that is provided by the state.  





2.1 Caps Any experience related to limits on the benefits the insurance company 
will cover in a plan year.   
2.2 Coinsurance Any experience related to coinsurance.  
2.3 Copay Any experience related to copays.  
2.4 Deductible Any experience related to deductibles.  
2.5 Other Descriptions of other types of financial payments or cost sharing an 
individual has experienced.  
2.6 Out of pocket 
maximum 
Descriptions of the limit an individual is required to pay before 
insurance will cover the rest of their costs within a plan year.   
2.7 Premium Any experience related to premiums.  
2.8 Savings Any experience related to an individual’s actions to attempt to save 
money for the insurance company. This could include deciding not to 
submit certain expenses or specific strategies meant to save money.  
3. Coverage Descriptions of the health insurance coverage experience for medical 
procedures, equipment, providers, and services.  
3.1 Consistent The participant indicates that they always had coverage and did not 
experience a period of interrupted health coverage.   
3.2 Equipment Experiences related to access to equipment and medical supplies.  
3.3 Hospital Experiences related to access and coverage of hospital services.  
3.4 Nursing Experiences related to access and coverage for nursing services.  
3.5 Providers Experiences related to access and coverage to medical providers. 
3.6 Therapy Experiences related to access and coverage for therapy; including 
physical, occupational, and speech therapies.  




medical procedures, pharmaceutical products, and vaccines.  
4. Genetics Any description of genetic testing, genome sequencing, or the impact 
of genetic information on decision making.    




Real, perceived, or hypothetical health consequences of delays or 
denials in coverage.  
5.2 Diagnosis Experiences related to how diagnosis impacted the patient’s access or 
coverage experience. 
5.3 Doctor rec Information related to the difference between a medical professional’s 
recommendations for care and the health insurance company’s 
coverage.  
5.4 Transition Experiences related to the coverage and care transitions patients 
experience as they age.  
6. Health 
literacy 
An individual’s ability to obtain, process, and understand health 
information and systems to make health decisions.  
6.1 Knowledge Descriptions related to how well an individual understands the 
healthcare system and the health insurance system.  
6.2 Navigating Experiences related to how an individual can navigate and work 
through the health insurance system to access healthcare.   
7. Improvement
s 
Discussion on any improvements that the participant believes should 
be made to the system.  
7.1 Automated Discussion related to changes to automate aspects of the system.  
7.2 Centralized Discussion related to centralizing resources or information.  
7.3 Communicati
on 
Discussion related to improving communication.  




7.5 Knowledge  Discussion related to changes in the insurance company’s knowledge 
or comprehension of the experience of patients and families.  
7.6 Main thing The thing that the individuals indicated would be the most critical 
change to improve their insurance experience.  
7.7 Personnel Discussion related to changes in personnel at health insurance 
companies.  
7.8 Time Discussion related to changes in the time associated with interacting 
with the system.  
7.9 Transparency Discussion related to improvements around transparency.  
7.10 User friendly Discussions related to how user friendly the system is to navigate.   
8. Involvement Experiences related to an individual’s level of involvement or 
participation in achieving coverage or in medical decision making for 
their loved one.  
8.1 Active Experiences where an individual took an active role in health insurance 
coverage or access.  
8.2 Passive Experiences where an individual took a passive role in health 
insurance coverage or access.  
8.3 Preplanning Experiences where an individual took action prior to when coverage 
was necessary.   
9. Life Descriptions of the interplay between life decisions and the medical or 
health insurance experience.   
9.1 Children Descriptions related to family planning or having additional children. 
9.2 Home Descriptions related to setting up a home or where an individual is 
willing to live.  
9.3 Mental health Descriptions related to mental health.  





9.5 Work Descriptions related to employment decisions.  
10. Obstacles Descriptions of the challenges participants have experienced while 
trying to access their health insurance coverage or experiences faced 
while working with their health insurance company.  
10.1 Approval Experiences related to what the insurance company is willing to 
approve for coverage.  
10.2 Bounced Experiences related to how many people or departments the participant 
must interact with before their issue is resolved, or their question is 
answered.  
10.3 Changes Experiences related to changes in the insurance policy or company.  
10.4 Coding Descriptions related to how coding impacted insurance coverage.  
10.5 Cost Experiences related to the cost or financial barriers to coverage.   
10.6 Coverage Descriptions related to the coverage experience when an individual is 




Experiences related to the providing the necessary documentation or 
paperwork.   
10.8 Incomplete 
information 
Experiences related to receiving incomplete information from the 
insurance company.  
10.9 Knowledge Experiences related to the overall knowledge or comprehension of the 
people working within the insurance system.  
10.10 Network Experiences related to accessing providers or treatment centers that are 
not in the network for the insurance plan.  
10.11 Options Descriptions related to available options for choosing insurance 
providers or the flexibility of the type of plans that are available.  
10.12 Qualifying Experiences related to gaining coverage or qualifying for a certain type 
of insurance plan.  




10.14 Time Experiences related to the time it takes to interact with insurance, to 
navigate the system, or to access coverage. 
11. Politics Any discussion on how politics play into feelings of uncertainty or 
decision making.  
11.1 Pre-existing 
condition 
Any discussion related to preexisting conditions. 
 
12. Privilege Any discussion related to how the participant’s experience compares to 
others or the struggle that other individuals may be experiencing. This 
could be in relation to their successes or their commentary about 
overall challenges for others in a similar position.   
13. Recruitment Offers to help recruit for the study. 
14. Satisfaction Descriptions related to an individual’s satisfaction related to health 
insurance.  
14.1 Trust Descriptions related to the trust an individual has for their insurance 
company.  
15. Support Experiences related to receiving emotional, mental, or informational 
support. This includes both finding and accessing health services and 
utilizing connections to feel better about an individual’s situation. This 
does not include financial support.  
15.1 Coordination Any description of multiple parties working together to solve a health 
insurance issue or provide emotional support.  
15.2 Early 
intervention 




Experiences related to support provided by the health insurance 
company.  
15.4 Organizations Experiences related to support provided by organizations, including 
non-profits or other support agencies. 
15.5 Peers Experiences related to support received by peers, friends, or family.  




including physicians, nurses, therapists, or other hospital workers.    
15.7 School Experiences related to support provided by the school system or 
individuals who work at the school.   
15.8 Social media Experiences related to support received through social media.  
15.9 Social 
workers 
Experiences related to support provided by social workers.  
16. Type Descriptions related to the type of insurance coverage an individual 
has for their child.  
16.1 Employer Experiences related to employer sponsored health insurance.  
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